Scriptaid isosteres and their use in therapy

ABSTRACT

Compounds of the invention are of the formula 
     
       
         
         
             
             
         
       
     
     wherein:
            is a double bond and X is C; or      is a single bond and X is N, CH or CQR 1 ; and
 
wherein:
   n is 1 to 10;   R is H or QR 1 ;   each R′ is independently selected from H and QR 1 ;   each Q is independently selected from a bond, CO, NH, S, SO, SO 2  or O;   each R 1  is independently selected from C 1 -C 10  alkyl, C 2 -C 10  alkenyl, C 2 -C 10  alkynyl, substituted or unsubstituted aryl or heteroaryl, acyl, C 1 -C 10  cycloalkyl, halogen, C 1 -C 10  alkylaryl or C 1 -C 10  heterocycloalkyl;   L is a nitrogen-containing heteroaryl; and   W is a zinc-chelating residue;   or a pharmaceutically acceptable salt thereof. The compounds are useful in therapy.

CROSS REFERENCE TO A RELATED APPLICATION

This application is a continuation application of Ser. No. 13/145,250,filed Aug. 30, 2011; which is a National Stage Application ofInternational Application Number PCT/GB2010/050116, filed Jan. 26, 2010;which claims priority to Great Britain Application No. 0901406.9, filedJan. 28, 2009 and Great Britain Application No. 0912383.7, filed Jul.16, 2009; all of which are incorporated herein by reference in theirentirety.

FIELD OF THE INVENTION

The present invention relates to novel compounds which act as inhibitorsof histone deacetylase (HDAC) and therefore have therapeutic utility.

BACKGROUND OF THE INVENTION

HDACs are zinc metalloenzymes that catalyse the hydrolysis of acetylatedlysine residues. In histones, this returns lysines to their protonatedstate and is a global mechanism of eukaryotic transcriptional control,resulting in tight packaging of DNA in the nucleosome. Additionally,reversible lysine acetylation is an important regulatory process fornon-histone proteins. Thus, compounds which are able to modulate HDAChave important therapeutic potential.

SUMMARY OF THE INVENTION

A compound of the formula

wherein:

is a double bond and X is C; or

is a single bond and X is N, CH or CQR₁; and

wherein:

n is 1 to 10;

R is H or QR₁;

each R′ is independently selected from H and QR₁;

each Q is independently selected from a bond, CO, NH, S, SO, SO₂ or O;

each R₁ is independently selected from C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl,C₂-C₁₀ alkynyl, substituted or unsubstituted aryl or heteroaryl, acyl,C₁-C₁₀ cycloalkyl, halogen, C₁-C₁₀ alkylaryl or C₁-C₁₀ heterocycloalkyl;

L is a nitrogen-containing heteroaryl; and

W is a zinc-chelating residue;

or a pharmaceutically acceptable salt thereof.

The compounds of the invention may be useful as an inhibitor of HDAC.

DESCRIPTION OF THE INVENTION

As used in this specification, and unless otherwise defined, the term“alkyl” refers to a straight or branched chain alkyl moiety having fromone to ten carbon atoms, including, for example, methyl, ethyl, propyl,isopropyl, butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, and decyl.Preferably it is C₁-C₆ alkyl group or moiety which can be linear orbranched. Typically, it is a C₁-C₄ alkyl group or moiety, for examplemethyl, ethyl, n-propyl, i-propyl, n-butyl, sec-butyl and t-butyl.Preferred examples include methyl, i-propyl and t-butyl.

The term “alkenyl” refers to a straight or branched chain alkyl moietyhaving two to ten carbon atoms and having in addition one double bond,of either E or Z stereochemistry where applicable. Preferably, it is aC₂-C₆ alkenyl group or moiety which can be linear or branched.Typically, it is a C₂-C₄ alkenyl group or moiety. It is preferred thatthe alkenyl radicals are mono or diunsaturated, more preferablymonounsaturated. Examples include vinyl, allyl, 1-propenyl, isopropenyl,1-butenyl, 2-butenyl, 3-butenyl, and 2-butenyl, and 2-methyl-2-propenyl.

The term “alkynyl” refers to a straight or branched chain alkyl moietyhaving two to ten carbon atoms and having in addition one triple bond.Preferably, it is C₂₋₆ alkynyl, and more preferably C₂₋₄ alkynyl. Thisterm includes, for example, ethynyl, 1-propargyl, and 1- and 2-butynyl.

The term “aryl” refers to an optionally substituted phenyl or naphthylgroup, including benzofused systems.

The term “heteroaryl” refers to an aromatic system of between 5 and 12ring atoms, of which at least one atom is selected from O, N and S. Theterm includes benzofused systems. This term includes, for example,pyridyl, pyrrolyl, pyridinyl, diazolyl, diazinyl, triazolyl, triazinyl,tetrazolyl, furanyl, oxazolyl, isoxazolyl, oxadiazolyl, benzofusedfuranyl, thiophenyl, pyridyl, pyrrolyl, pyridazinyl, pyrazinyl,pyrimidinyl, benzofused pyridyl, indolyl, benzofuranyl, quinolinyl,isoquinolinyl or quinazolinyl. Such rings can be linked either throughcarbon or nitrogen. The “heteroaryl” may be optionally substituted.

The term “heterocycloalkyl” means any partially or fully saturatedanalogue of “heteroaryl”. “Heterocyclic” is generic to heteroaryl andheterocycloalkyl. “Cycloalkyl” means a carbocyclic analogue of aheterocycle, e.g. cyclopentyl or cylohexyl. “Cycloalkenyl” is as forcycloalkyl but contains one or more double bonds in the ring,

The term “heteroalkyl” refers to an alkyl chain wherein one or morecarbon atoms have been replaced by a heteroatom such as N, O or S, withthe proviso that when more than one of such heteroatoms are present,they are separated by at least two carbon atoms.

Some of the groups defined above, such as aryl and heteroaryl may be“optionally substituted”. Examples of such substituents are alkyl,alkenyl, alkynyl, heteroaryl, and such groups including a heteroatomsuch as N, O or S, and halogen, e.g. F or Cl.

In a preferred embodiment, at least one L is selected from pyridyl or abenzofused pyridyl. In a more preferred embodiment, at least one L isselected from:

The group W is a zinc-chelating residue. Preferably, it is ametallophile capable of binding with zinc in the active site of HDAC.Suitable metallophiles are known to those skilled in the art.

In a preferred embodiment, W is selected from:

Preferably, W is —COOH, —CONHOH, CONHSO₂CH₃, —CONHNHSO₂CH₃, —CONHNH₂,—CONH(2-pyridyl) or —NHCONHOH. Even more preferably, W is —CONHOH.

Preferably, n is 3 to 6.

In a preferred embodiment, at least one R′ is H, C₁-C₁₀ alkyl orO−(C₁-C₁₀ alkyl). Preferably, at least one R′ is substituted orunsubstituted aryl or O-(substituted or unsubstituted aryl). Preferably,at least one R′ is aryl or O-aryl, each of which may be substituted witha halogen, amino or C₁-C₁₀ alkyl. The aryl may be substituted anyposition. The aryl may be mono-, bis-, or tri-substituted.

R′ may be substituted onto any of the ring atoms of the L group, i.e.the nitrogen-containing heteroaryl group.

A pharmaceutical composition of the invention comprises a compound asdefined above, and a pharmaceutically acceptable carrier or diluent. Apharmaceutical composition of the invention typically contains up to 85wt % of a compound of the invention. More typically, it contains up to50 wt % of a compound of the invention. Preferred pharmaceuticalcompositions are sterile and pyrogen-free. Further, the pharmaceuticalcompositions provided by the invention typically contain a compound ofthe invention which is a substantially pure optical isomer. Preferably,the pharmaceutical composition comprises a pharmaceutically acceptablesalt form of a compound of the invention.

As used herein, a pharmaceutically acceptable salt is a salt with apharmaceutically acceptable acid or base. Pharmaceutically acceptableacids include both inorganic acids such as hydrochloric, sulphuric,phosphoric, diphosphoric, hydrobromic or nitric acid and organic acidssuch as citric, fumaric, maleic, malic, ascorbic, succinic, tartaric,benzoic, acetic, methanesulphonic, ethanesulphonic, salicylic, stearic,benzenesulphonic or p-toluenesulphonic acid. Pharmaceutically acceptablebases include alkali metal (e.g. sodium or potassium) and alkali earthmetal (e.g. calcium or magnesium) hydroxides and organic bases such asalkyl amines, aryl amines or heterocyclic amines.

For the avoidance of doubt, the present invention also embraces prodrugswhich react in vivo to give a compound of the present invention.

The compounds of the present invention are found to be inhibitors ofHDAC. The compounds of the present invention are thereforetherapeutically useful in the treatment of conditions affected by HDACactivity.

The compounds of the invention may be prepared by synthetic routes thatwill be apparent to those skilled in the art, e.g. based on theExamples.

The compounds of the present invention are found to be inhibitors ofHDAC. The compounds of the present invention are thereforetherapeutically useful.

The compounds of the invention and compositions comprising them may beadministered in a variety of dosage forms. In one embodiment, apharmaceutical composition comprising a compound of the invention may beformulated in a format suitable for oral, rectal, parenteral, intranasalor transdermal administration or administration by inhalation or bysuppository. Typical routes of administration are parenteral, intranasalor transdermal administration or administration by inhalation.

The compounds of the invention can be administered orally, for exampleas tablets, troches, lozenges, aqueous or oily suspensions, dispersiblepowders or granules. Preferred pharmaceutical compositions of theinvention are compositions suitable for oral administration, for exampletablets and capsules.

The compounds of the invention may also be administered parenterally,whether subcutaneously, intravenously, intramuscularly, intrasternally,transdermally or by infusion techniques. The compounds may also beadministered as suppositories.

The compounds of the invention may also be administered by inhalation.An advantage of inhaled medications is their direct delivery to the areaof rich blood supply in comparison to many medications taken by oralroute. Thus, the absorption is very rapid as the alveoli have anenormous surface area and rich blood supply and first pass metabolism isbypassed. A further advantage may be to treat diseases of the pulmonarysystem, such that delivering drugs by inhalation delivers them to theproximity of the cells which are required to be treated.

The present invention also provides an inhalation device containing sucha pharmaceutical composition. Typically said device is a metered doseinhaler (MDI), which contains a pharmaceutically acceptable chemicalpropellant to push the medication out of the inhaler.

The compounds of the invention may also be administered by intranasaladministration. The nasal cavity's highly permeable tissue is veryreceptive to medication and absorbs it quickly and efficiently, more sothan drugs in tablet form. Nasal drug delivery is less painful andinvasive than injections, generating less anxiety among patients. Bythis method absorption is very rapid and first pass metabolism isusually bypassed, thus reducing inter-patient variability. Further, thepresent invention also provides an intranasal device containing such apharmaceutical composition.

The compounds of the invention may also be administered by transdermaladministration. The present invention therefore also provides atransdermal patch containing a compound of the invention.

The compounds of the invention may also be administered by sublingualadministration. The present invention therefore also provides asub-lingual tablet comprising a compound of the invention.

A compound of the invention may also be formulated with an agent whichreduces degradation of the substance by processes other than the normalmetabolism of the patient, such as anti-bacterial agents, or inhibitorsof protease enzymes which might be the present in the patient or incommensural or parasite organisms living on or within the patient, andwhich are capable of degrading the compound.

Liquid dispersions for oral administration may be syrups, emulsions andsuspensions.

Suspensions and emulsions may contain as carrier, for example a naturalgum, agar, sodium alginate, pectin, methylcellulose,carboxymethylcellulose, or polyvinyl alcohol. The suspension orsolutions for intramuscular injections may contain, together with theactive compound, a pharmaceutically acceptable carrier, e.g. sterilewater, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and ifdesired, a suitable amount of lidocaine hydrochloride.

Solutions for injection or infusion may contain as carrier, for example,sterile water or preferably they may be in the form of sterile, aqueous,isotonic saline solutions.

In one embodiment the compounds of the present invention may be used incombination with another known inhibitor of HDAC, such as SAHA. In thisembodiment, the combination product may be formulated such that itcomprises each of the medicaments for simultaneous, separate orsequential use.

The compounds of the present invention can be used in both the treatmentand prevention of cancer and can be used in a monotherapy or in acombination therapy. When used in a combination therapy, the compoundsof the present invention are typically used together with small chemicalcompounds such as platinum complexes, anti-metabolites, DNAtopoisomerase inhibitors, radiation, antibody-based therapies (forexample herceptin and rituximab), anti-cancer vaccination, gene therapy,cellular therapies, hormone therapies or cytokine therapy.

In one embodiment of the invention a compound of the invention is usedin combination with another chemotherapeutic or antineoplastic agent inthe treatment of a cancer. Examples of such other chemotherapeutic orantineoplastic agents include platinum complexes including cisplatin andcarboplatin, mitoxantrone, vinca alkaloids for example vincristine andvinblastine, anthracycline antibiotics for example daunorubicin anddoxorubicin, alkylating agents for example chlorambucil and melphalan,taxanes for example paclitaxel, antifolates for example methotrexate andtomudex, epipodophyllotoxins for example etoposide, camptothecins forexample irinotecan and its active metabolite SN38 and DNA methylationinhibitors for example the DNA methylation inhibitors disclosed inWO02/085400.

According to the invention, therefore, products are provided whichcontain a compound of the invention and another chemotherapeutic orantineoplastic agent as a combined preparation for simultaneous,separate or sequential use in alleviating a cancer. Also providedaccording to the invention is the use of compound of the invention inthe manufacture of a medicament for use in the alleviation of cancer bycoadministration with another chemotherapeutic or antineoplastic agent.The compound of the invention and the said other agent may beadministrated in any order. In both these cases the compound of theinvention and the other agent may be administered together or, ifseparately, in any order as determined by a physician.

HDAC is believed to contribute to the pathology and/or symptomology ofseveral different diseases such that reduction of the activity of HDACin a subject through inhibition of HDAC may be used to therapeuticallyaddress these disease states. Examples of various diseases that may betreated using the HDAC inhibitors of the present invention are describedherein.

One set of indications that HDAC inhibitors of the present invention maybe used to treat is those involving undesirable or uncontrolled cellproliferation. Such indications include benign tumours, various types ofcancers such as primary tumours and tumour metastasis, restenosis (e.g.coronary, carotid, and cerebral lesions), abnormal stimulation ofendothelial cells (atherosclerosis), insults to body tissue due tosurgery, abnormal wound healing, abnormal angiogenesis, diseases thatproduce fibrosis of tissue, repetitive motion disorders, disorders oftissues that are not highly vascularized, and proliferative responsesassociated with organ transplants. More specific indications for HDACinhibitors include, but are not limited to prostate cancer, lung cancer,acute leukaemia, multiple myeloma, bladder carcinoma, renal carcinoma,breast carcinoma, colorectal carcinoma, neuroblastoma and melanoma.

In one embodiment, a method is provided for treating diseases associatedwith undesired and uncontrolled cell proliferation. The method comprisesadministering to a subject suffering from uncontrolled cellproliferation a therapeutically effective amount of a HDAC inhibitoraccording to the present invention, such that said uncontrolled cellproliferation is reduced. The particular dosage of the inhibitor to beused will depend on the severity of the disease state, the route ofadministration, and related factors that can be determined by theattending physician. Generally, acceptable and effective daily doses areamounts sufficient to effectively slow or eliminate uncontrolled cellproliferation.

HDAC inhibitors according to the present invention may also be used inconjunction with other agents to inhibit undesirable and uncontrolledcell proliferation. Examples of other anti-cell proliferation agentsthat may be used in conjunction with the HDAC inhibitors of the presentinvention include, but are not limited to, retinoid acid and derivativesthereof, 2-methoxyestradiol, Angiostatin™ protein, Endostatin™ protein,suramin, squalamine, tissue inhibitor of metalloproteinase-I, tissueinhibitor of metalloproteinase-2, plasminogen activator inhibitor-1,plasminogen activator inhibitor-2, cartilage-derived inhibitor,paclitaxel, platelet factor 4, protamine sulfate (clupeine), sulfatedchitin derivatives (prepared from queen crab shells), sulfatedpolysaccharide peptidoglycan complex (sp-pg), staurosporine, modulatorsof matrix metabolism, including for example, proline analogs((1-azetidine-2-carboxylic acid (LACA), cishydroxyproline,d,I-3,4-dehydroproline, thiaproline), beta-aminopropionitrile fumarate,4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; methotrexate, mitoxantrone,heparin, interferons, 2 macroglobulin-serum, chimp-3, chymostatin,beta-cyclodextrin tetradecasulfate, eponemycin; fumagillin, gold sodiumthiomalate, d-penicillamine (CDPT), beta-1-anticollagenase-serum,alpha-2-antiplasmin, bisantrene, lobenzarit disodium,n-(2-carboxyphenyl-4-chloroanthronilic acid disodium or “CCA”,thalidomide; angiostatic steroid, carboxyaminoimidazole;metalloproteinase inhibitors such as BB94. Other anti-angiogenesisagents that may be used include antibodies, preferably monoclonalantibodies against these angiogenic growth factors: bFGF, aFGF, FGF-5,VEGF isoforms, VEGF-C, HGF/SF and Ang-1/Ang-2. Ferrara N. and Alitalo,K. “Clinical application of angiogenic growth factors and theirinhibitors” (1999) Nature Medicine 5:1359-1364.

Generally, cells in benign tumours retain their differentiated featuresand do not divide in a completely uncontrolled manner. A benign tumouris usually localized and nonmetastatic. Specific types of benign tumoursthat can be treated using HDAC inhibitors of the present inventioninclude hemangiomas, hepatocellular adenoma, cavernous haemangioma,focal nodular hyperplasia, acoustic neuromas, neurofibroma, bile ductadenoma, bile duct cystanoma, fibroma, lipomas, leiomyomas,mesotheliomas, teratomas, myxomas, nodular regenerative hyperplasia,trachomas and pyogenic granulomas.

In the case of malignant tumors, cells become undifferentiated, do notrespond to the body's growth control signals, and multiply in anuncontrolled manner. Malignant tumors are invasive and capable ofspreading to distant sites (metastasizing). Malignant tumors aregenerally divided into two categories: primary and secondary. Primarytumors arise directly from the tissue in which they are found. Secondarytumours, or metastases, are tumours that originated elsewhere in thebody but have now spread to distant organs. Common routes for metastasisare direct growth into adjacent structures, spread through the vascularor lymphatic systems, and tracking along tissue planes and body spaces(peritoneal fluid, cerebrospinal fluid, etc.).

Specific types of cancers or malignant tumours, either primary orsecondary, that can be treated using the HDAC inhibitors of the presentinvention include, but are not limited to, leukaemia, breast cancer,skin cancer, bone cancer, prostate cancer, liver cancer, lung cancer,brain cancer, cancer of the larynx, gallbladder, pancreas, rectum,parathyroid, thyroid, adrenal, neural tissue, head and neck, colon,stomach, bronchi, kidneys, basal cell carcinoma, squamous cell carcinomaof both ulcerating and papillary type, metastatic skin carcinoma, osteosarcoma, Ewing's sarcoma, veticulum cell sarcoma, myeloma, giant celltumour, small-cell lung tumour, gallstones, islet cell tumour, primarybrain tumour, acute and chronic lymphocytic and granulocytic tumours,hairy-cell tumour, adenoma, hyperplasia, medullary carcinoma,pheochromocytoma, mucosal neuromas, intestinal ganglloneuromas,hyperplastic corneal nerve tumour, marfanoid habitus tumour, Wilms'tumour, seminoma, ovarian tumour, leiomyomater tumour, cervicaldysplasia and in situ carcinoma, neuroblastoma, retinoblastoma, softtissue sarcoma, malignant carcinoid, topical skin lesion, mycosisfungoide, rhabdomyosarcoma, Kaposi's sarcoma, osteogenic and othersarcoma, malignant hypercalcemia, renal cell tumour, polycythermia vera,adenocarcinoma, glioblastoma multiforma, leukemias, lymphomas, malignantmelanomas, epidermoid carcinomas, and other carcinomas and sarcomas.

The HDAC inhibitors of the present invention may also be used to treatabnormal cell proliferation due to insults to body tissue duringsurgery. These insults may arise as a result of a variety of surgicalprocedures such as joint surgery, bowel surgery, and cheloid scarring.Diseases that produce fibrotic tissue that may be treated using the HDACinhibitors of the present invention include emphysema. Repetitive motiondisorders that may be treated using the present invention include carpaltunnel syndrome. An example of a cell proliferative disorder that may betreated using the invention is a bone tumour.

Proliferative responses associated with organ transplantation that maybe treated using HDAC inhibitors of the invention include proliferativeresponses contributing to potential organ rejections or associatedcomplications. Specifically, these proliferative responses may occurduring transplantation of the heart, lung, liver, kidney, and other bodyorgans or organ systems.

Abnormal angiogenesis that may be treated using this invention includethose abnormal angiogenesis accompanying rheumatoid arthritis,ischemic-reperfusion related brain edema and injury, cortical ischemia,ovarian hyperplasia and hypervascularity, polycystic ovary syndrome,endometriosis, psoriasis, diabetic retinopathy, and other ocularangiogenic diseases such as retinopathy of prematurity (retrolentalfibroplastic), macular degeneration, corneal graft rejection,neuroscular glaucoma and Oster Webber syndrome.

Examples of diseases associated with uncontrolled angiogenesis that maybe treated according to the present invention include, but are notlimited to retinal/choroidal neovascularization and cornealneovascularization. Examples of diseases which include some component ofretinal/choroidal neovascularization include, but are not limited to,Best's diseases, myopia, optic pits, Stargart's diseases, Paget'sdisease, vein occlusion, artery occlusion, sickle cell anemia, sarcoid,syphilis, pseudoxanthoma elasticum carotid apo structive diseases,chronic uveitis/vitritis, mycobacterial infections, Lyme's disease,systemic lupus erythematosus, retinopathy of prematurity, Eale'sdisease, diabetic retinopathy, macular degeneration, Bechet's diseases,infections causing a retinitis or chroiditis, presumed ocularhistoplasmosis, pars planitis, chronic retinal detachment,hyperviscosity syndromes, toxoplasmosis, trauma and post-lasercomplications, diseases associated with rubesis (neovascularization ofthe angle) and diseases caused by the abnormal proliferation offibrovascular or fibrous tissue including all forms of proliferativevitreoretinopathy. Examples of corneal neovascularization include, butare not limited to, epidemic keratoconjunctivitis, Vitamin A deficiency,contact lens overwear, atopic keratitis, superior limbic keratitis,pterygium keratitis sicca, sjogrens, acne rosacea, phylectenulosis,diabetic retinopathy, retinopathy of prematurity, corneal graftrejection, Mooren ulcer, Terrien's marginal degeneration, marginalkeratolysis, polyarteritis, Wegener sarcoidosis, Scleritis, periphigoidradial keratotomy, neovascular glaucoma and retrolental fibroplasia,syphilis, Mycobacteria infections, lipid degeneration, chemical burns,bacterial ulcers, fungal ulcers, Herpes simplex infections, Herpeszoster infections, protozoan infections and Kaposi sarcoma.

Chronic inflammatory diseases associated with uncontrolled angiogenesismay also be treated using HDAC inhibitors of the present invention.Chronic inflammation depends on continuous formation of capillarysprouts to maintain an influx of inflammatory cells. The influx andpresence of the inflammatory cells produce granulomas and thus maintainsthe chronic inflammatory state. Inhibition of angiogenesis using a HDACinhibitor alone or in conjunction with other anti-inflammatory agentsmay prevent the formation of the granulosmas and thus alleviate thedisease. Examples of chronic inflammatory diseases include, but are notlimited to, inflammatory bowel diseases such as Crohn's disease andulcerative colitis, psoriasis, sarcoidosis, and rheumatoid arthritis.

Inflammatory bowel diseases such as Crohn's disease and ulcerativecolitis are characterized by chronic inflammation and angiogenesis atvarious sites in the gastrointestinal tract. For example, Crohn'sdisease occurs as a chronic transmural inflammatory disease that mostcommonly affects the distal ileum and colon but may also occur in anypart of the gastrointestinal tract from the mouth to the anus andperianal area. Patients with Crohn's disease generally have chronicdiarrhoea associated with abdominal pain, fever, anorexia, weight lossand abdominal swelling. Ulcerative colitis is also a chronic,nonspecific, inflammatory and ulcerative disease arising in the colonicmucosa and is characterized by the presence of bloody diarrhoea. Theseinflammatory bowel diseases are generally caused by chronicgranulomatous inflammation throughout the gastrointestinal tract,involving new capillary sprouts surrounded by a cylinder of inflammatorycells. Inhibition of angiogenesis by these inhibitors should inhibit theformation of the sprouts and prevent the formation of granulomas.Inflammatory bowel diseases also exhibit extra intestinalmanifestations, such as skin lesions. Such lesions are characterized byinflammation and angiogenesis and can occur at many sites other thegastrointestinal tract. Inhibition of angiogenesis by HDAC inhibitorsaccording to the present invention can reduce the influx of inflammatorycells and prevent lesion formation.

Sarcoidosis, another chronic inflammatory disease, is characterized as amultisystem granulomatous disorder. The granulomas of this disease canform anywhere in the body. Thus, the symptoms depend on the site of thegranulomas and whether the disease is active. The granulomas are createdby the angiogenic capillary sprouts providing a constant supply ofinflammatory cells. By using HDAC inhibitors according to the presentinvention to inhibit angiogenesis, such granulomas formation can beinhibited. Psoriasis, also a chronic and recurrent inflammatory disease,is characterized by papules and plaques of various sizes. Treatmentusing these inhibitors alone or in conjunction with otheranti-inflammatory agents should prevent the formation of new bloodvessels necessary to maintain the characteristic lesions and provide thepatient relief from the symptoms.

Rheumatoid arthritis (RA) is also a chronic inflammatory diseasecharacterized by non-specific inflammation of the peripheral joints. Itis believed that the blood vessels in the synovial lining of the jointsundergo angiogenesis. In addition to forming new vascular networks, theendothelial cells release factors and reactive oxygen species that leadto pannus growth and cartilage destruction. The factors involved inangiogenesis may actively contribute to, and help maintain, thechronically inflamed state of rheumatoid arthritis. Treatment using HDACinhibitors according to the present invention alone or in conjunctionwith other anti-RA agents may prevent the formation of new blood vesselsnecessary to maintain the chronic inflammation.

The compounds of the present invention can further be used in thetreatment of cardiac/vasculature diseases such as hypertrophy,hypertension, myocardial infarction, reperfusion, ischaemic heartdisease, angina, arryhtmias, hypercholestremia, atherosclerosis andstroke. The compounds can further be used to treat neurodegenerativedisorders/CNS disorders such as acute and chronic neurological diseases,including stroke, Huntington's disease, Amyotrophic Lateral Sclerosisand Alzheimer's disease.

The compounds of the present invention can also be used as antimicrobialagents, for example antibacterial agents. The invention therefore alsoprovides a compound for use in the treatment of a bacterial infection.The compounds of the present invention can be used as anti-infectiouscompounds against viral, bacterial, fungal and parasitic infections.Examples of infections include protozoal parasitic infections (includingplasmodium, cryptosporidium parvum, toxoplasma gondii, sarcocystisneurona and Eimeria sp.)

The compounds of the present invention are particularly suitable for thetreatment of undesirable or uncontrolled cell proliferation, preferablyfor the treatment of benign tumours/hyperplasias and malignant tumours,more preferably for the treatment of malignant tumours and mostpreferably for the treatment of chronic lymphocytic leukaemia (CLL),breast cancer, prostate cancer, ovarian cancer, mesothelioma, T-celllymphoma.

In a preferred embodiment of the invention, the compounds of theinvention are used to alleviate cancer, cardiac hypertrophy, chronicheart failure, an inflammatory condition, a cardiovascular disease, ahaemoglobinopathy, a thalassemia, a sickle cell disease, a CNS disorder,an autoimmune disease, organ transplant rejection, diabetes,osteoporosis, MDS, benign prostatic hyperplasia, oral leukoplakia, agenetically related metabolic disorder, an infection, Rubens-Taybi,fragile X syndrome, or alpha-1 antitrypsin deficiency, or to acceleratewound healing, to protect hair follicles or as an immunosuppressant.

Typically, said inflammatory condition is a skin inflammatory condition(for example psoriasis, acne and eczema), asthma, chronic obstructivepulmonary disease (COPD), rheumatoid arthritis (RA), inflammatory boweldisease (IBD), Crohn's disease or colitis.

Typically, said cancer is chronic lymphocytic leukaemia, breast cancer,prostate cancer, ovarian cancer, mesothelioma or T-cell lymphoma.

Typically, said cardiovascular disease is hypertension, myocardialinfarction (MI), ischemic heart disease (IHD) (reperfusion), anginapectoris, arrhythmia, hypercholestremia, hyperlipidaemia,atherosclerosis, stroke, myocarditis, congestive heart failure, primaryand secondary i.e. dilated (congestive) cardiomyopathy, hypertrophiccardiomyopathy, restrictive cardiomyopathy, peripheral vascular disease,tachycardia, high blood pressure or thrombosis.

Typically, said genetically related metabolic disorder is cysticfibrosis (CF), peroxisome biogenesis disorder or adrenoleukodystrophy.

Typically, the compounds of the invention are used as animmunosuppressant following organ transplant.

Typically, said infection is a viral, bacterial, fungal or parasiticinfection, in particular an infection by S aureus, P acne, candida oraspergillus.

Typically, said CNS disorder is Huntingdon's disease, Alzheimer'sdisease, multiple sclerosis or amyotrophic lateral sclerosis.

In this embodiment, the compounds of the invention may be used toalleviate cancer, cardiac hypertrophy, chronic heart failure, aninflammatory condition, a cardiovascular disease, a haemoglobinopathy, athalassemia, a sickle cell disease, a CNS disorder, an autoimmunedisease, diabetes or osteoporosis, or are used as an immunosuppressant.

The compounds of the invention may also be used to alleviate chroniclymphocytic leukaemia (CLL), breast cancer, prostate cancer, ovariancancer, mesothelioma, T-cell lymphoma, cardiac hypertrophy, chronicheart failure or a skin inflammatory condition, in particular psoriasis,acne or eczema.

The compounds of the present invention can be used in the treatment ofanimals, preferably in the treatment of mammals and more preferably inthe treatment of humans.

The compounds of the invention may, where appropriate, be usedprophylactically to reduce the incidence of such conditions.

In use, a therapeutically effective amount of a compound of theinvention is administered to a patient. A typical dose is from about0.001 to 50 mg per kg of body weight, according to the activity of thespecific compound, the age, weight and conditions of the subject to betreated, the type and severity of the disease and the frequency androute of administration.

Compounds of the invention may be tested for HDAC inhibitory activity byany suitable assay, e.g. the assay described in WO2008/062201. By thisassay, the compounds of the Examples each have IC₅₀ values of below 1 M.

The following Examples illustrate the invention.

Example 1 N-Hydroxy-7,7-di(pyridin-2-yl)hept-6-enamide

IC₅₀, Total HDAC (HeLa Nuclear Extracts)=0.95 μM IC₅₀, HDAC1=0.158 μMIC₅₀, HDAC6=0.068 μM IC₅₀, MCF7 Breast Tumour Cell ProliferationInhibition=0.6 μM Example 2 6-(Dipyridin-2-ylamino)-N-hydroxyhexanamide

IC₅₀, Total HDAC (HeLa Nuclear Extracts)=2.49 μM IC₅₀, MCF7 BreastTumour Cell Proliferation Inhibition=2.34 μM Example 37-(Dipyridin-2-ylamino)-N-hydroxyheptanamide

IC₅₀, Total HDAC (HeLa Nuclear Extracts)=0.245 μM IC₅₀, HDAC1=0.458 μMIC₅₀, HDAC2=1.54 μM IC₅₀, HDAC3=0.710 μM IC₅₀, HDAC4=0.307 μM IC₅₀,HDAC5=0.458 μM IC₅₀, HDAC6=0.009 μM IC₅₀, MCF7 Breast Tumour CellProliferation Inhibition=0.466 μM

IC₅₀, TNFα inhibition (LPS-stimulated human PBMCs)=0.1 μM

Example 4 N-Hydroxy-7-(pyridin-2-yl(quinolin-2-yl)amino)heptanamide

IC₅₀, Total HDAC (HeLa Nuclear Extracts)=0.081 μM IC₅₀, HDAC1=0.071 μMIC₅₀, HDAC2=0.212 μM IC₅₀, HDAC3=0.062 μM IC₅₀, HDAC4=0.545 μM IC₅₀,HDAC5=0.123 μM IC₅₀, HDAC6=0.016 μM IC₅₀, HDAC7=0.157 μM IC₅₀,HDAC8=0.312 μM IC₅₀, HDAC9=0.090 μM IC₅₀, HDAC10=0.126 μM IC₅₀,HDAC11=0.112 μM IC₅₀, MCF7 Breast Tumour Cell ProliferationInhibition=0.146 μM Example 5N-Hydroxy-8,8-di(pyridin-2-yl)oct-7-enamide

IC₅₀, Total HDAC (HeLa Nuclear Extracts)=0.415 μM IC₅₀, HDAC1=0.642 μMIC₅₀, HDAC6=0.022 μM Example 6N-Hydroxy-8,8-di(pyridin-2-yl)oct-7-enamide

IC₅₀, Total HDAC (HeLa Nuclear Extracts)=0.396 μM IC₅₀, MCF7 BreastTumour Cell Proliferation Inhibition=0.445 μM Example 7N-Hydroxy-7-((4-methylpyridin-2-yl) (pyridin-2-yl)amino)heptanamide

IC₅₀, Total HDAC (HeLa Nuclear Extracts)=0.778 μM IC₅₀, MCF7 BreastTumour Cell Proliferation Inhibition=0.448 μM Example 8N-Hydroxy-7-((4-phenylpyridin-2-yl)(pyridin-2-yl)amino)heptanamide

IC₅₀, Total HDAC (HeLa Nuclear Extracts)=0.493 μM IC₅₀, HDAC1=0.116 μMIC₅₀, HDAC6=0.019 μM IC₅₀, MCF7 Breast Tumour Cell ProliferationInhibition=1.05 μM Example 9N-Hydroxy-7-((5-methylpyridin-2-yl)(pyridin-2-yl)amino)heptanamide

IC₅₀, Total HDAC (HeLa Nuclear Extracts)=0.337 μM IC₅₀, HDAC1=0.453 μMIC₅₀, HDAC2=1.137 μM IC₅₀, HDAC6=0.031 μM IC₅₀, HDAC9=0.759 μM IC₅₀,MCF7 Breast Tumour Cell Proliferation Inhibition=0.697 μM Example 107-((5-(Benzyloxy)pyridin-2-yl)(pyridin-2-yl)amino)-N-hydroxyheptanamide

IC₅₀, Total HDAC (HeLa Nuclear Extracts)=1.07 μM IC₅₀, HDAC1=0.182 μMIC₅₀, HDAC6=0.057 μM IC₅₀, MCF7 Breast Tumour Cell ProliferationInhibition=0.285 μM Example 11N-Hydroxy-7-((5-methoxypyridin-2-yl)(pyridin-2-yl)amino)heptanamide

IC₅₀, Total HDAC (HeLa Nuclear Extracts)=0.406 μM IC₅₀, HDAC1=0.182 μMIC₅₀, HDAC2=0.883 μM IC₅₀, HDAC6=0.013 μM IC₅₀, HDAC9=0.759 μM IC₅₀,MCF7 Breast Tumour Cell Proliferation Inhibition=0.292 μM Example 12N-Hydroxy-7-((5-phenylpyridin-2-yl)(pyridin-2-yl)amino)heptanamide

IC₅₀, Total HDAC (HeLa Nuclear Extracts)=0.310 μM IC₅₀, MCF7 BreastTumour Cell Proliferation Inhibition=0.081 μM Example 137-((5-(4-Fluorophenyl)pyridin-2-yl)(pyridin-2-yl)amino)-N-hydroxyheptanamide

IC₅₀, Total HDAC (HeLa Nuclear Extracts)=0.521 μM IC₅₀, MCF7 BreastTumour Cell Proliferation Inhibition=0.357 μM Example 147-(Isoquinolin-3-yl-pyridin-2-yl-amino)-heptanoic acid hydroxyamide

IC₅₀, Total HDAC (HeLa Nuclear Extracts)=0.337 μM IC₅₀, HDAC1=0.064 μMIC₅₀, HDAC2=0.306 μM IC₅₀, HDAC6=0.002 μM IC₅₀, HDAC9=0.145 μM IC₅₀,MCF7 Breast Tumour Cell Proliferation Inhibition=0.169 μM Example 157-[(4-Benzyloxy-pyridin-2-yl)-pyridin-2-yl-amino]-heptanoic acidhydroxyamide

IC₅₀, Total HDAC (HeLa Nuclear Extracts)=1.26 μM IC₅₀, HDAC1=0.151 μMIC₅₀, HDAC2=0.612 μM IC₅₀, HDAC6=0.003 μM IC₅₀, HDAC9=0.423 μM IC₅₀,MCF7 Breast Tumour Cell Proliferation Inhibition=0.411 μM Example 167-[(4-Methoxy-pyridin-2-yl)-pyridin-2-yl-amino]-heptanoic acidhydroxyamide

IC₅₀, Total HDAC (HeLa Nuclear Extracts)=1.076 μM IC₅₀, MCF7 BreastTumour Cell Proliferation Inhibition=1.09 μM Example 177-[(4-Ethoxy-pyridin-2-yl)-pyridin-2-yl-amino]-heptanoic acidhydroxyamide

IC₅₀, Total HDAC (HeLa Nuclear Extracts)=0.598 μM IC₅₀, MCF7 BreastTumour Cell Proliferation Inhibition=0.456 μM Example 187-[(4-Propoxy-pyridin-2-yl)-pyridin-2-yl-amino]-heptanoic acidhydroxyamide

IC₅₀, Total HDAC (HeLa Nuclear Extracts)=0.822 μM IC₅₀, MCF7 BreastTumour Cell Proliferation Inhibition=0.574 μM Example 197-[(4-Isopropoxy-pyridin-2-yl)-pyridin-2-yl-amino]-heptanoic acidhydroxyamide

IC₅₀, Total HDAC (HeLa Nuclear Extracts)=0.326 μM IC₅₀, MCF7 BreastTumour Cell Proliferation Inhibition=0.478 μM Example 207-(Pyridin-3-yl-pyridin-2-yl-amino)-heptanoic acid hydroxyamide

IC₅₀, Total HDAC (HeLa Nuclear Extracts)=0.539 μM Example 217-{[4-(4-Fluoro-phenyl)-pyridin-2-yl]-pyridin-2-yl-amino}-heptanoic acidhydroxyamide

IC₅₀, Total HDAC (HeLa Nuclear Extracts)=1.08 μM Example 227-{[4-(4-Amino-phenyl)-pyridin-2-yl]-pyridin-2-yl-amino}-heptanoic acidhydroxyamide

IC₅₀, Total HDAC (HeLa Nuclear Extracts)=0.298 μM IC₅₀, MCF7 BreastTumour Cell Proliferation Inhibition=0.039 μM Example 237-[Pyridin-2-yl-(4-p-tolyl-pyridin-2-yl)-amino]-heptanoic acidhydroxyamide

IC₅₀, Total HDAC (HeLa Nuclear Extracts)=1.06 μM IC₅₀, MCF7 BreastTumour Cell Proliferation Inhibition=0.077 μM Example 247-[Pyridin-2-yl-(4-o-tolyl-pyridin-2-yl)-amino]-heptanoic acidhydroxyamide

IC₅₀, Total HDAC (HeLa Nuclear Extracts)=1.62 μM IC₅₀, MCF7 BreastTumour Cell Proliferation Inhibition=0.20 μM Example 257-{[4-(2-Chloro-phenyl)-pyridin-2-yl]-pyridin-2-yl-amino}-heptanoic acidhydroxyamide

IC₅₀, Total HDAC (HeLa Nuclear Extracts)=1.08 μM IC₅₀, MCF7 BreastTumour Cell Proliferation Inhibition=0.21 μM Example 267-{[4-(2-Fluoro-phenyl)-pyridin-2-yl]-pyridin-2-yl-amino}-heptanoic acidhydroxyamide

IC₅₀, MCF7 Breast Tumour Cell Proliferation Inhibition=0.20 μM Example27 7-[Pyridin-2-yl-(4-m-tolyl-pyridin-2-yl)-amino]-heptanoic acidhydroxyamide

IC₅₀, Total HDAC (HeLa Nuclear Extracts)=1.68 μM IC₅₀, MCF7 BreastTumour Cell Proliferation Inhibition=0.081 μM Preparative Methods andAnalytical Data Example 1 N-Hydroxy-7,7-di(pyridin-2-yl)hept-6-enamide

Methyl 6-triphenylphosphonium bromide hexanoate (II)

Methyl 6-bromohexanoate, I, (500 mg, 2.38 mmol) and PPh₃ (624 mg, 2.38mmol) were added to acetonitrile (15 mL) and the mixture was stirredunder an Ar(g) at reflux for 22 h. The solvent was subsequently removedby evaporation under reduced pressure, and the resulting phosphoniumbromide derivative II was dried under high vacuum.

7,7-Di-pyridin-2-yl-hept-6-enoic acid methyl ester (III)

NHMDS (2.26 mL, 2.26 mmol) as a solution in THF was added to methyl6-triphenylphosphonium bromide hexanoate II (1.072 g, 2.38 mmol) in THF(8 mL) at 0° C. under Ar(g). After 15 min, di-pyridin-2-yl-methanone(220 mg, 1.2 mmol) in THF (4 mL) was added; the reaction mixture wasstirred for 1 h, and was then allowed to warm to rt. After 20 hstirring, water (15 mL) and EtOAc (15 mL) were added, the phases wereseparated, and the aqueous phase was extracted with EtOAc (2×10 mL). Theorganic phases were combined, dried over MgSO₄, filtered, and thenevaporated under reduced pressure. The resulting residue was purified bysilica gel column chromatography using CH₂Cl₂/MeOH (100:0.5 to 100:2) aseluant to furnish III as a colourless oil (155 mg, 44%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.72 (d, J=4.8 Hz, 1H), 8.58 (d, J=4.8Hz, 1H), 7.69-7.80 (m, 2H), 7.44-7.53 (m, 2H), 7.24-7.32 (m, 2H), 6.93(t, J=7.7 Hz, 1H), 2.24-2.29 (m, 2H), 2.19 (q, J=7.6 Hz, 2H), 1.58-1.69(m, 2H), 1.51-1.58 (m, 2H). MW: 296.36. LCMS (ES). found 297.3 [MH]⁺.

7,7-Di-pyridin-2-yl-hept-6-enoic acid (IV)

LiOH (10 mg, 0.42 mmol) in water (0.2 mL) was added to III (25 mg, 0.085mmol) in THF (0.8 mL) at rt. After 19 h, the reaction mixture wasneutralized with 2N HCl, poured onto brine (2 mL), and EtOAc (3 mL) wasadded. The phases were separated and the aqueous phase was extractedwith EtOAc (2×3 mL). The organic phases were combined, dried over MgSO₄,filtered, and then evaporated under reduced pressure. The resultingresidue was then purified by silica gel column chromatography usingCH₂Cl₂/MeOH (100:2 to 100:4) as eluant to furnish IV as a colourless oil(11.3 mg, 46%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.74 (dt, J=4.8, 1.6 Hz, 1H), 8.62 (dd,J=5.0, 1.1 Hz, 1H), 7.80 (td, J=7.7, 1.7 Hz, 1H), 7.70-7.76 (m, 1H),7.61 (td, J=7.7, 1.8 Hz, 1H), 7.44-7.55 (m, 1H), 7.14-7.21 (m, 1H), 7.01(d, J=8.0 Hz, 1H), 6.89 (t, J=7.6 Hz, 1H), 2.29 (t, J=7.2 Hz, 2H), 2.20(q, J=7.2 Hz, 2H), 1.61-1.70 (m, 2H), 1.53-1.61 (m, 2H), 1.43-1.50 (m,1H). MW: 282.34. LCMS (ES). found 283.3 [MH]⁺.

7,7-Di-pyridin-2-yl-hept-6-enoic acid hydroxyamide (V)

HONH₂ (50% aqueous, 0.3 mL) was added to IV (32 mg, 0.1 mmol) in DMF(0.3 mL) and THF (0.3 mL) at 0° C. The reaction mixture was stirred atrt for 17 h, after which brine (3 mL) and EtOAc (3 mL) were added. Thephases were separated, and the aqueous phase was extracted with EtOAc(2×3 mL). The organic phases were then combined, dried over MgSO₄,filtered, and subsequently evaporated under reduced pressure. Theresulting residue was purified by silica gel column chromatography usingCH₂Cl₂/MeOH (100:3 to 100:10) as eluant to furnish V, a colourless oil(9.6 mg, 30%).

¹H NMR (300 MHz, CDCl₃) δ_(H): 8.79 (d, J=5.5 Hz, 1H), 8.68 (dd, J=5.3,0.9 Hz, 1H), 7.94-8.01 (m, 1H), 7.86 (td, J=7.8, 1.6 Hz, 1H), 7.65-7.77(m, 1H), 7.42-7.53 (m, 3H), 7.10 (t, J=7.5 Hz, 1H), 2.12-2.35 (m, 3H),1.54-1.76 (m, 4H), 1.35-1.53 (m, 1H). MW 297.35. LCMS (ES). found 298.0[MH]⁺.

Example 2 6-(Dipyridin-2-ylamino)-N-hydroxyhexanamide

6-(Di-pyridin-2-yl-amino)-hexanoic acid methyl ester (II)

NaH (112 mg, 2.92 mmol) was added to di-pyridin-2-yl-amine (500 mg, 2.92mmol) in DMF (10 mL) at rt. After 10 min, KI (485 mg, 2.92 mmol) andmethyl 6-bromohexanoate, I (0.464 mL, 2.92 mmol) were added, and thereaction mixture was stirred at 90° C. for 21 h. Brine (200 mL) andEtOAc (200 mL) were then added, the phases were separated, and theaqueous phase was extracted with EtOAc (100 mL). The organic phases werecombined, dried over MgSO₄, filtered, and subsequently evaporated underreduced pressure. The resulting residue was purified by silica gelcolumn chromatography using CH₂Cl₂/MeOH (100:0.5 to 100:1) as eluant tofurnish II as a colourless oil (206 mg, 24%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.35 (dd, J=2.5, 1.8 Hz, 2H), 7.47-7.56(m, 2H), 7.07 (d, J=9.2 Hz, 2H), 6.86 (dd, J=6.4, 5.6 Hz, 2H), 4.15-4.21(m, 2H), 3.65 (s, 3H), 2.29 (t, J=7.5 Hz, 2H), 1.61-1.77 (m, 4H),1.34-1.45 (m, 2H). MW: 299.37. LCMS (ES). found 300.3 [MH]⁺, 322.3[MNa]⁺.

6-(Di-pyridin-2-yl-amino)-hexanoic acid (III)

LiOH (12 mg, 0.50 mmol) in water (0.3 mL) was added to II (33 mg, 0.11mmol) in THF (0.8 mL) at rt. After 2 h, the reaction mixture wasneutralized with 2N HCl, and was then poured onto brine (5 mL), andEtOAc (5 mL) was added. The phases were separated and the aqueous phasewas extracted with EtOAc (2×2 mL). The organic phases were combined,dried over MgSO₄, filtered, and then evaporated under reduced pressure.The resulting residue was purified by silica gel column chromatographyusing CH₂Cl₂/MeOH (100:1 to 100:4) as eluant to furnish III as acolourless oil (18.1 mg, 58%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.37 (ddd, J=5.0, 2.0, 0.7 Hz, 2H),7.50-7.58 (m, 2H), 7.06 (d, J=8.4 Hz, 2H), 6.88 (ddd, J=7.2, 5.1, 0.8Hz, 2H), 2.33 (t, J=7.5 Hz, 2H), 1.62-1.78 (m, 4H), 1.42 (quin, J=7.7Hz, 2H). MW: 285.34. LCMS (ES). found 286.3 [MH]⁺, 284.3 [MH]⁻.

6-(Di-pyridin-2-yl-amino)-hexanoic acid hydroxyamide (IV)

HONH₂ (50% aqueous, 0.3 mL) was added to II (32 mg, 0.1 mmol) in DMF(0.3 mL) and THF (0.3 mL) at 0° C. The reaction mixture was agitated atrt for 17 h. Brine (3 mL) and EtOAc (3 mL) were added, the phases wereseparated, and the aqueous phase was extracted with EtOAc (2×3 mL). Theorganic phases were combined, dried over MgSO₄, filtered then evaporatedunder reduced pressure. The residue was purified by silica gel columnchromatography with CH₂Cl₂/MeOH (100:3 to 100:10) to furnish IV as acolourless oil (9.6 mg, 30%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.37 (d, J=3.3 Hz, 2H), 7.58 (t, J=7.5Hz, 2H), 7.06 (d, J=8.21 Hz, 2H), 6.90-6.97 (m, 2H), 4.15 (t, J=7.5 Hz,2H), 2.12-2.24 (m, 2H), 1.61-1.78 (m, 4H), 1.34-1.45 (m, 2H). MW:300.36. LCMS (ES). found 301.2 [MH]⁺, 323.1 [MNa]⁺.

Example 3 7-(Dipyridin-2-ylamino)-N-hydroxyheptanamide

7-(Di-pyridin-2-yl-amino)-heptanoic acid ethyl ester (II)

NaH (112 mg, 2.92 mmol) was added to di-pyridyl-2-yl-amine, I, (500 mg,2.92 mmol) in DMF (10 mL) at rt. After 10 min, KI (727 mg, 4.38 mmol)and ethyl 7-bromoheptanoate (0.854 mL, 4.38 mmol) were added, and thereaction mixture was stirred at 90° C. for 18 h. Aqueous 0.1M Na₂S₂O₃(100 mL) and EtOAc (100 mL) were added, the phases were separated, andthe organic phase was washed with brine (100 mL) then dried over MgSO₄,filtered, and subsequently evaporated under reduced pressure. Theresulting residue was purified by silica gel column chromatographyeluting with hexane/EtOAc (90:10 to 75:25) to furnish II as a colourlessoil (490 mg, 51%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.35 (dd, J=1.8, 5.3 Hz, 2H), 7.52 (dt,J=2.0, 7.0 Hz, 2H), 7.08 (d, J=8.0 Hz, 2H), 6.86 (dd, J=5.5, 7.0 Hz,2H), 4.18 (t, J=7.5 Hz, 2H), 4.12 (q, J=7.0 Hz, 2H), 2.27 (t, J=7.5 Hz,2H), 1.71 (td, J=7.0, 14.6 Hz, 2H), 1.61 (td, J=7.3, 14.6 Hz, 2H),1.43-1.30 (m, 4H), 1.25 (t, J=7.0 Hz, 3H). MW: 327.42. LCMS (ES). found327.9 [MH]⁺.

7-(Di-pyridin-2-yl-amino)-heptanoic acid hydroxyamide (III)

HONH₂ (50% aqueous, 2 mL) was added to II (524 mg, 1.60 mmol) in DMF(0.5 mL) and MeOH (2 mL) at rt. The reaction mixture was stirred for 72h, after which the solvents were evaporated under reduced pressure. Theresulting residue was dissolved and co-evaporated with toluene (2×10 mL)then was purified by silica gel column chromatography eluting withCH₂Cl₂/MeOH (100:4 then 100:8) to furnish III as a colourless oil(425.79 mg, 85%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.35 (d, J=4.0 Hz, 2H), 7.55 (t, J=7.3Hz, 2H), 7.05 (d, J=8.5 Hz, 2H), 6.89 (t, J=5.5 Hz, 2H), 4.16 (t, J=7.5Hz, 2H), 2.23-2.05 (m, 2H), 1.75-1.56 (m, J=7.0, 15.6 Hz, 4H), 1.44-1.27(m, 4H). MW: 314.38. LCMS (ES). found 315.2 [M H]⁺.

Example 4 N-Hydroxy-7-(pyridin-2-yl(quinolin-2-yl)amino)heptanamide

Pyridin-2-yl-quinolin-2-yl-amine (II)

2-Bromoquinoline, I (500 mg, 2.40 mmol), 2-aminopyridine (249 mg, 2.64mmol), tBuOK (404 mg, 3.60 mmol), (±)-BINAP (6 mg, 0.01 mmol) andPd₂(dba)₃ (5.5 mg, 0.006 mmol) were stirred in toluene (10 mL) at 90° C.under Ar(g) for 21 h. The reaction mixture was then diluted with CH₂Cl₂(10 mL) and silica was added, followed by the removal of the solventunder reduced pressure. The resulting dry load material was purified bysilica gel column chromatography eluting with CH₂Cl₂/MeOH (100:1 then100:2) to furnish II as a colourless oil (344 mg, 45%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.40-8.26 (m, 2H), 8.03 (d, J=8.5 Hz,1H), 7.86 (d, J=8.0 Hz, 1H), 7.79-7.68 (m, 2H), 7.65 (t, J=7.5 Hz, 1H),7.38 (t, J=7.0 Hz, 2H), 7.00-6.90 (m, 1H). MW: 221.26. LCMS (ES). found222.1 [MH]⁺.

7-(Pyridin-2-yl-quinolin-2-yl-amino)-heptanoic acid ethyl ester (III)

NaH (35 mg, 0.91 mmol) was added to II (344 mg, 0.91 mmol) in DMF (5 mL)at rt. After 10 min, KI (227 mg, 1.37 mmol) and ethyl 7-bromoheptanoate(0.267 mL, 1.37 mmol) were added. The reaction mixture was stirred at90° C. for 19 h after which 0.1 M Na₂S₂O₃ (50 mL) and EtOAc (50 mL) wereadded; the phases were then separated and the aqueous phase extractedwith EtOAc (2×25 mL). The organic phases were combined then dried overMgSO₄, filtered, and subsequently evaporated under reduced pressure. Theresulting residue was purified by silica gel column chromatography,eluting with hexane/EtOAc (90:10 to 85:15), to furnish III as acolourless oil (189 mg, 55%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.41 (dd, J=1.5, 5.0 Hz, 1H), 7.90-7.80(m, 2H), 7.67 (d, J=8.0 Hz, 1H), 7.63-7.56 (m, 2H), 7.36-7.31 (m, J=7.5,7.5 Hz, 1H), 7.19 (t, J=8.8 Hz, 2H), 6.95 (dd, J=5.3, 6.8 Hz, 1H), 4.35(t, J=7.5 Hz, 2H), 4.12 (q, J=7.4 Hz, 2H), 2.28 (t, J=7.5 Hz, 2H), 1.79(quin, J=7.3 Hz, 2H), 1.63 (quin, J=7.4 Hz, 2H), 1.48-1.35 (m, 4H), 1.25(t, J=7.0 Hz, 3H). MW: 377.48. LCMS (ES). found 378.2 [MH]⁺.

7-(Pyridin-2-yl-quinolin-2-yl-amino)-heptanoic acid hydroxyamide (IV)

HONH₂ (50% aqueous, 2 mL) was added to III (90 mg, 0.24 mmol) in DMF(0.5 mL) and MeOH (2 mL) at rt. The reaction mixture was stirred for 48h, after which the solvents were evaporated under reduced pressure. Theresulting residue was dissolved and co-evaporated with toluene (2×10 mL)then was purified by silica gel column chromatography eluting withCH₂Cl₂/MeOH (100:4) to furnish IV as a colourless oil (66.43 mg, 76%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.43 (dd, J=1.5, 5.0 Hz, 1H), 7.99-7.92(m, J=6.0 Hz, 1H), 7.90 (d, J=9.0 Hz, 1H), 7.68 (d, J=8.0 Hz, 1H),7.65-7.58 (m, J=7.0, 7.0 Hz, 2H), 7.37 (t, J=7.5 Hz, 1H), 7.18 (d, J=8.5Hz, 1H), 7.12 (d, J=9.0 Hz, 1H), 7.05-6.98 (m, 1H), 4.36 (t, J=7.3 Hz,2H), 2.13 (t, J=7.3 Hz, 2H), 1.77 (quin, J=7.4 Hz, 2H), 1.63 (td, J=7.0,14.1 Hz, 2H), 1.47-1.32 (m, 4H). MW: 364.44. LCMS (ES). found 365.2[MH]⁺.

Example 5 N-Hydroxy-8,8-di(pyridin-2-yl)oct-7-enamide

(6-Ethoxycarbonyl-hexyl)-triphenyl-phosphonium bromide (I)

Ethyl-7-bromoheptanoate (2.5 g, 10.54 mmol) and PPh₃ (2.764 g, 10.54mmol) were added to acetonitrile (50 mL) and the mixture was stirredunder Ar(g) at reflux for 18 h. The solvent was subsequently removed byevaporation under reduced pressure, and the resulting phosphoniumbromide derivative I was dried under high vacuum.

MW: 499.42. LCMS (ES). found 419.2 [MH]⁺.

8,8-Di-pyridin-2-yl-oct-7-enoic acid ethyl ester (II)

NaHMDS (10.01 mL, 10.01 mmol) as a solution in THF was added to(6-ethoxycarbonyl-hexyl)-triphenyl-phosphonium bromide 1 (10.54 mmol) inTHF (40 mL) at −78° C. under Ar(g). After 30 min,di-pyridin-2-yl-methanone (1.437 g, 7.81 mmol) in THF (5 mL) was added;the reaction was stirred for 2 h, and was then allowed to warm to rt.After 17 h, saturated aqueous NH₄Cl (250 mL) and EtOAc (150 mL) wereadded; the phases were separated, and the aqueous phase was extractedwith EtOAc (2×100 mL). The organic phases were combined, dried overMgSO₄, filtered, and then evaporated under reduced pressure. Theresulting residue was purified by silica gel column chromatographyeluting with CH₂Cl₂/MeOH (100:0.5 to 100:2) to furnish II as a palebrown oil (990 mg, 40%).

MW: 324.42. LCMS (ES). found 325.2 [MH]⁺.

8,8-Di-pyridin-2-yl-oct-7-enoic acid hydroxyamide (III)

HONH₂ (50% aqueous, 0.5 mL) was added to II (68 mg, 0.21 mmol) in MeOH(0.5 mL) at rt. The reaction mixture was stirred for 72 h, after whichthe solvents were evaporated under reduced pressure. The resultingresidue was dissolved and co-evaporated with toluene (2×5 mL), then waspurified by silica gel column chromatography eluting with CH₂Cl₂/MeOH(100:1 to 100:10) to furnish III as a colourless oil (12 mg, 18%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.71 (d, J=4.0 Hz, 1H), 8.57 (d, J=4.5Hz, 1H), 7.80 (dt, J=1.3, 7.7 Hz, 1H), 7.58 (dt, J=1.8, 7.7 Hz, 1H),7.36-7.29 (m, 2H), 7.16 (dd, J=5.0, 7.0 Hz, 1H), 6.95 (d, J=8.0 Hz, 1H),6.85 (t, J=7.5 Hz, 1H), 2.21-2.08 (m, 4H), 1.61-1.44 (m, 4H), 1.34-1.25(m, 2H). MW: 311.38. LCMS (ES). found 312.1 [MH]⁺.

Example 6 N-Hydroxy-8,8-di(pyridin-2-yl)oct-7-enamide

Ethyl 8,8-bis(pyridin-2-yl)octanoate (II)

NaBH₄ (43 mg, 1.14 mmol) and NiCl₂.6H₂O (135 mg, 0.57 mmol) were addedto I (124 mg, 0.38 mmol, preparation of which is outlined above inExample 5) in THF (4 mL) at 0° C. under Ar(g). After 2 h of stirring at0° C. the reaction was carefully quenched with 1N HCl (2 mL), thenneutralized with saturated NaHCO₃, and EtOAc (10 mL) was added. Thephases were separated and the aqueous phase was extracted with EtOAc (10mL). The organic phases were combined, dried over MgSO₄, filtered, andthen evaporated under reduced pressure. The resulting residue waspurified by silica gel column chromatography eluting with hexane/EtOAc(20:80) to furnish II as a colourless oil (34 mg, 27%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.59-8.50 (m, 2H), 7.65 (t, J=7.5 Hz,2H), 7.45 (m, 2H), 7.20-7.12 (m, 2H), 4.46-4.33 (m, 1H), 4.11 (q, J=7.0Hz, 2H), 2.29-2.22 (m, 4H), 1.57 (quin, J=7.5 Hz, 2H), 1.39-1.31 (m,2H), 1.30-1.19 (m, 5H). MW: 326.43. LCMS (ES). found 327.2 [MH]⁺.

N-Hydroxy-8,8-di(pyridin-2-yl)oct-7-enamide (III)

HONH₂ (50% aqueous, 1 mL) was added to II (34 mg, 0.1 mmol) in MeOH (1mL) at rt. The reaction mixture was stirred for 48 h, after which thesolvents were evaporated under reduced pressure. The resulting residuewas dissolved and co-evaporated with toluene (2×5 mL) then was purifiedby silica gel column chromatography eluting with CH₂Cl₂/MeOH (100:3 to100:5) to furnish III as a colourless oil (16 mg, 52%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.55 (d, J=4.5 Hz, 2H), 7.67 (dt, J=2.0,7.5 Hz, 2H), 7.45 (d, J=7.5 Hz, 2H), 7.18 (ddd, J=1.0, 5.0, 7.5 Hz, 2H),4.45 (t, J=8.0 Hz, 1H), 2.23 (quin, J=7.5 Hz, 4H), 1.64 (quin, J=6.9 Hz,2H), 1.42-1.21 (m, 6H). MW: 313.39. LCMS (ES). found 314.2 [MH]⁺.

Example 7N-Hydroxy-7-((4-methylpyridin-2-yl)(pyridin-2-yl)amino)heptanamide

(4-Methyl-pyridin-2-yl)-pyridin-2-yl-amine (I)

2-Bromo-4-methylpyridine (0.195 mL, 1.74 mmol), 2-aminopyridine (180 mg,1.91 mmol), potassium tert-butoxide (293 mg, 2.61 mmol), (±)-BINAP (4.3mg, 6.96 mmol) and Pd₂(dba)₃ (4 mg, 4.35 mmol) were stirred in toluene(2.5 mL) at 90° C. under Ar(g). After 17 h stirring, the reactionmixture was diluted with CH₂Cl₂ (2.5 mL) and silica was added. Thesolvent was removed under reduced pressure and the resulting dry loadedmaterial purified by silica gel column chromatography eluting withCH₂Cl₂/MeOH (100:1 to 100:2) to furnish I as a yellow solid (249 mg,77%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.27 (d, J=4.5 Hz, 1H), 8.12 (d, J=5.0Hz, 1H), 7.64-7.54 (m, 2H), 7.36 (s, 1H), 6.85 (t, J=6.3 Hz, 1H), 6.70(d, J=5.5 Hz, 1H), 2.34 (s, 3H). MW: 185.23. LCMS (ES). found 186.1[MH]⁺.

7-[(4-Methyl-pyridin-2-yl)-pyridin-2-yl-amino]heptanoic acid ethyl ester(II)

NaH (53 mg, 1.34 mmol) was added to 1 (249 mg, 1.34 mmol) in DMF (5 mL)at rt. After 10 min, KI (335 mg, 2.02 mmol) and ethyl 7-bromoheptanoate(0.40 mL, 2.02 mmol) were added, and the reaction mixture was stirred at90° C. for 22 h. Aqueous 0.1M Na₂S₂O₃ (50 mL) and EtOAc (50 mL) wereadded, the phases were separated, and the aqueous phase was extractedwith EtOAc (2×25 mL). The organic phases were combined, dried overMgSO₄, filtered, and subsequently evaporated under reduced pressure. Theresulting residue was purified by silica gel column chromatographyeluting with hexane/EtOAc (90:10 to 75:25) to furnish II as a colourlessoil (101 mg, 22%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.33 (dd, J=1.8, 4.8 Hz, 1H), 8.21 (d,J=5.5 Hz, 1H), 7.53-7.45 (m, 1H), 7.02 (d, J=8.5 Hz, 1H), 6.89 (s, 1H),6.82 (dd, J=5.0, 7.0 Hz, 1H), 6.71 (d, J=5.0 Hz, 1H), 4.18-4.08 (m, 4H),2.31-2.23 (m, 5H), 1.69 (quin, J=7.3 Hz, 2H), 1.60 (quin, J=7.3 Hz, 2H),1.41-1.29 (m, 4H), 1.24 (t, J=7.0 Hz, 3H). MW: 341.25. LCMS (ES). found342.2 [MH]⁺.

N-Hydroxy-7-((4-methylpyridin-2-yl)(pyridin-2-yl)amino)heptanamide (III)

HONH₂ (50% aqueous, 2 mL) was added to II (101 mg, 0.3 mmol) in MeOH (2mL) at rt. The reaction mixture was stirred for 72 h, after which thesolvents were evaporated under reduced pressure. The resulting residuewas dissolved and co-evaporated with toluene (2×5 mL) then was purifiedby silica gel column chromatography eluting with CH₂Cl₂/MeOH (100:3 to100:7) to furnish III as a colourless oil (46 mg, 47%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.31 (dd, J=1.5, 5.0 Hz, 1H), 8.20 (d,J=5.0 Hz, 1H), 7.53-7.46 (m, 1H), 6.98 (d, J=8.5 Hz, 1H), 6.86 (s, 1H),6.83 (dd, J=5.0, 7.0 Hz, 1H), 6.72 (d, J=4.5 Hz, 1H), 4.09 (t, J=7.5 Hz,2H), 2.26 (s, 3H), 2.11-2.03 (m, 2H), 1.69-1.52 (m, 4H), 1.38-1.23 (m,4H). MW: 328.41. LCMS (ES). found 329.2 [MH]⁺.

Example 8N-Hydroxy-7-((4-phenylpyridin-2-yl)(pyridin-2-yl)amino)heptanamide

(4-Phenyl-pyridin-2-yl)-pyridin-2-yl-amine (I)

2-Bromo-4-phenylpyridine (280 mg, 1.19 mmol), 2-aminopyridine (124 mg,1.31 mmol), potassium tert-butoxide (201 mg, 1.79 mmol), (±)-BINAP (3mg, 0.05 mmol) and Pd₂(dba)₃ (2.7 mg, 0.03 mmol) were stirred in toluene(2.5 mL) at 90° C. under Ar(g). After 17 h stirring, the reactionmixture was diluted with CH₂Cl₂ (2.5 mL) and silica was added. Thesolvent was removed under reduced pressure and the resulting dry loadedmaterial purified by silica gel column chromatography, eluting withCH₂Cl₂/MeOH (100:2), to furnish I as a yellow solid (183 mg, 62%).

1H NMR (400 MHz, CDCl₃) δ_(H): 8.29 (t, J=5.8 Hz, 2H), 7.91-7.78 (m,1H), 7.72-7.58 (m, 4H), 7.54-7.39 (m, 3H), 7.12 (d, J=4.5 Hz, 1H),6.94-6.85 (m, 1H). MW: 247.29 LCMS (ES). found 248.1. [MH]⁺.

7-[(4-Phenyl-pyridin-2-yl)-pyridin-2-yl-amino]-heptanoic acid ethylester (II)

NaH (29 mg, 0.73 mmol) was added to I (180 mg, 0.73 mmol) in DMF (7.5mL) at rt. After 10 min, KI (183 mg, 1.1 mmol) and ethyl7-bromoheptanoate (0.21 mL, 1.1 mmol) were added, and the reactionmixture was stirred at 90° C. for 16 h. Aqueous 0.1M Na₂S₂O₃ (50 mL) andEtOAc (30 mL) were added, the phases were separated, and the aqueousphase was extracted with EtOAc (30 mL). Then the organic phases werecombined, dried over MgSO₄, filtered, and subsequently evaporated underreduced pressure. The resulting residue was purified by silica gelcolumn chromatography eluting with hexane/EtOAc (85:15 to 80:20) tofurnish II as a colourless oil (169 mg, 57%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.40 (d, J=5.5 Hz, 1H), 8.37 (dd, J=1.0,5.0 Hz, 1H), 7.59-7.50 (m, 3H), 7.48-7.37 (m, 3H), 7.28 (s, 1H), 7.13(d, J=8.5 Hz, 1H), 7.09 (dd, J=1.5, 5.0 Hz, 1H), 6.87 (dd, J=5.0, 6.5Hz, 1H), 4.23 (t, J=7.5 Hz, 2H), 4.11 (q, J=7.0 Hz, 2H), 2.27 (t, J=7.5Hz, 2H), 1.75 (quin, J=7.4 Hz, 2H), 1.61 (quin, J=7.5 Hz, 2H), 1.44-1.31(m, 4H), 1.24 (t, J=7.3 Hz, 3H). MW: 403.52. LCMS (ES). found 404.2[MH]⁺.

N-Hydroxy-7-((4-phenylpyridin-2-yl)(pyridin-2-yl)-amino)heptanamide(III)

HONH₂ (50% aqueous, 4 mL) was added to II (120 mg, 0.3 mmol) in MeOH (4mL) and DMF (2 mL) at rt. The reaction mixture was stirred for 24 h,after which the solvents were evaporated under reduced pressure. Theresulting residue was dissolved and co-evaporated with toluene (3×5 mL)then was purified by silica gel column chromatography eluting withCH₂Cl₂/MeOH (100:2 to 100:8) to furnish III as a yellow oil (28 mg,23%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.38 (d, J=5.5 Hz, 1H), 8.36 (d, J=5.0Hz, 1H), 7.61-7.48 (m, 3H), 7.47-7.35 (m, 3H), 7.23 (br. s., 1H),7.14-7.03 (m, 2H), 6.88 (dd, J=5.5, 6.5 Hz, 1H), 4.27-3.97 (m, 2H),2.16-1.96 (m, 2H), 1.78-1.65 (m, 2H), 1.64-1.54 (m, 2H), 1.44-1.13 (m,4H). MW: 390.48. LCMS (ES). found 391.2 [MH]⁺.

Example 9N-Hydroxy-7-((5-methylpyridin-2-yl)(pyridin-2-yl)amino)heptanamide

(5-Methyl-pyridin-2-yl)-pyridin-2-yl-amine (I)

2-Bromo-5-methylpyridine (300 mg, 1.74 mmol), 2-aminopyridine (180 mg,1.91 mmol), potassium tert-butoxide (293 mg, 2.61 mmol), (±)-BINAP (4.3mg, 0.07 mmol) and Pd₂(dba)₃ (4 mg, 0.05 mmol) were stirred in toluene(4 mL) at 90° C. under Ar(g). After 17 h stirring, the reaction wasdiluted with CH₂Cl₂ (5 mL), and silica was added. The solvent wasremoved under reduced pressure and the resulting dry loaded materialpurified by silica gel column chromatography eluting with CH₂Cl₂/MeOH(100:2) to furnish I as a yellow solid (187 mg, 58%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.24 (d, J=4.5 Hz, 1H), 8.08 (s, 1H),7.64-7.55 (m, 1H), 7.54-7.43 (m, 3H), 6.88-6.80 (m, 1H), 2.28 (s, 3H).MW: 185.23. LCMS (ES). found 186.1 [M H]⁺.

7-[(5-Methyl-pyridin-2-yl)-pyridin-2-yl-amino]heptanoic acid ethyl ester(II)

NaH (38 mg, 1.0 mmol) was added to I (187 mg, 1.0 mmol) in DMF (7.5 mL)at rt. After 10 min, KI (250 mg, 1.5 mmol) and ethyl 7-bromoheptanoate(0.29 mL, 1.5 mmol) were added, and the reaction mixture was stirred at90° C. for 17 h. Aqueous 0.1M Na₂S₂O₃ (30 mL) and EtOAc (25 mL) wereadded, the phases were separated, and the aqueous phase was extractedwith EtOAc (25 mL). Then the organic phases were combined, dried overMgSO₄, filtered, and subsequently evaporated under reduced pressure. Theresulting residue was purified by silica gel column chromatographyeluting with CH₂Cl₂/MeOH (100:1) to furnish II as a colourless oil (236mg, 70%). MW: 341.45. LCMS (ES). found 342.2 [MH]⁺.

N-Hydroxy-7-((5-methylpyridin-2-yl)(pyridin-2-yl)amino)heptanamide (III)

HONH₂ (50% aqueous, 1 mL) was added to II (50 mg, 0.15 mmol) in MeOH (1mL) and DMF (0.5 mL) at rt. The reaction mixture was stirred for 72 h,after which the solvents were evaporated under reduced pressure. Theresulting residue was dissolved and co-evaporated with toluene (3×5 mL)then was purified by silica gel column chromatography eluting withCH₂Cl₂/MeOH (100:2 to 100:8) to furnish III as a pale brown oil (37 mg,75%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 0.28 (d, J=4.5 Hz, 1H), 8.20 (br. s.,1H), 7.50-7.43 (m, 1H), 7.41 (dd, J=1.5, 8.0 Hz, 1H), 7.03 (d, J=8.5 Hz,1H), 6.89 (d, J=8.5 Hz, 1H), 6.78 (dd, J=5.3, 6.8 Hz, 1H), 4.16-4.03 (m,2H), 2.29 (s, 3H), 2.16-2.00 (m, 2H), 1.80-1.52 (m, J=7.0, 10.5 Hz, 4H),1.42-1.23 (m, 4H). MW: 328.41. LCMS (ES). found 329.2 [MH]⁺.

Example 107-((5-(Benzyloxy)pyridin-2-yl)(pyridin-2-yl)amino)-N-hydroxyheptanamide

5-Benzyloxy-2-bromo-pyridine (I)

2-Bromo-5-hydroxypyridine (347 mg, 2 mmol) in DMF (3 mL) was addeddropwise over a period of 10 min to a suspension of NaH (88 mg, 2.3mmol) in DMF (2 mL) at 0° C. under Ar(g). The reaction mixture was thenstirred at it for 10 min, after which it was again cooled down at 0° C.,and benzyl bromide (0.25 mL, 2.1 mmol) was added. The reaction mixturewas stirred at it for 2.5 h, after which it was poured onto brine (20mL) and EtOAc (20 mL) was added. The phases were separated and theaqueous phase was extracted with EtOAc (20 mL). The organic phases werecombined, dried over MgSO₄, filtered and subsequently evaporated underreduced pressure. The resulting residue was purified by silica gelcolumn chromatography eluting with hexane/EtOAc (95:5 to 90:10) tofurnish I as a colourless oil (380 mg, 72%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.14 (d, J=3.5 Hz, 1H), 7.46-7.29 (m,6H), 7.16 (dd, J=3.3, 8.8 Hz, 1H), 5.10 (s, 2H). MW: 264.12. LCMS (ES).found 265.0 [MH]⁺.

(5-Benzyloxy-pyridin-2-yl)-pyridin-2-yl-amine (II)

Compound I (370 mg, 1.40 mmol), 2-aminopyridine (145 mg, 1.54 mmol),tBuOK (235 mg, 2.10 mmol), (±)-BINAP (35 mg, 0.01 mmol) and Pd₂(dba)₃(32 mg, 0.006 mmol) were stirred in toluene (5 mL) at 90° C. under Ar(g)for 17 h. The reaction mixture was then diluted with CH₂Cl₂ (5 mL), andsilica was added followed by the removal of the solvent under reducedpressure. The resulting dry loaded material was purified by silica gelcolumn chromatography eluting with hexane/EtOAc (60:40 then 50:50) tofurnish II as a colourless oil (355 mg, 91%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.22 (dd, J=1.8, 4.8 Hz, 1H), 8.03 (d,J=3.5 Hz, 1H), 7.62-7.53 (m, 2H), 7.46-7.28 (m, 7H), 6.81 (dd, J=5.0,7.0 Hz, 1H), 5.09 (s, 2H). MW: 277.32. LCMS (ES). found 278.1 [MH]⁺.

7-[(5-Benzyloxy-pyridin-2-yl)-pyridin-2-yl-amino]-heptanoic acid ethylester (III)

NaH (48 mg, 1.26 6 mmol) was added to II (350 mg, 1.26 mmol) in DMF (6mL) at rt. After 10 min, KI (314 mg, 1.89 mmol) and ethyl7-bromoheptanoate (0.370 mL, 1.89 mmol) were added. The reaction mixturewas stirred at 90° C. for 18 h30 after which 0.1 M Na₂S₂O₃ (50 mL) andEtOAc (50 mL) were added, the phases were separated and the aqueousextracted with EtOAc (2×25 mL). The organic phases were combined thendried over MgSO₄, filtered, and subsequently evaporated under reducedpressure. The resulting residue was purified by silica gel columnchromatography eluting with hexane/EtOAc (80:20 then 70:30) to furnishIII as a colourless oil (308 mg, 56%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.25 (dd, J=1.5, 5.0 Hz, 1H), 8.19 (d,J=3.0 Hz, 1H), 7.47-7.33 (m, 6H), 7.26 (dd, J=3.0, 8.5 Hz, 1H), 7.13 (d,J=9.0 Hz, 1H), 6.77 (d, J=8.0 Hz, 1H), 6.71 (dd, J=5.3, 6.8 Hz, 1H),5.11 (s, 2H), 4.16-4.04 (m, 4H), 2.27 (t, J=7.5 Hz, 2H), 1.72-1.65 (m,2H), 1.61 (quin, J=7.5 Hz, 2H), 1.42-1.29 (m, 4H), 1.25 (t, J=7.0 Hz,3H). MW: 433.54. LCMS (ES). found 434.2 [MH]⁺.

7-((5-(Benzyloxy)pyridin-2-yl)(pyridin-2-yl)amino)-N-hydroxyheptanamide(IV)

HONH₂ (50% aqueous, 0.5 mL) was added to III (26 mg, 0.06 mmol) in DMF(0.2 mL) and MeOH (0.5 mL) at rt. The reaction mixture was stirred for72 h, after which the solvents were evaporated under reduced pressure.The resulting residue was dissolved and co-evaporated with toluene (2×10mL) then was purified by silica gel column chromatography eluting withCH₂Cl₂/MeOH (100:4 to 100:8) to furnish IV as a colourless oil (18.66mg, 74%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.29-8.23 (m, 1H), 8.22-8.17 (m, 1H),7.49-7.33 (m, 6H), 7.29 (dd, J=1.8, 8.8 Hz, 1H), 7.12 (d, J=8.5 Hz, 1H),6.78-6.69 (m, 2H), 5.12 (s, 2H), 4.15-4.01 (m, 2H), 2.18-2.10 (m, 2H),1.71-1.58 (m, 4H), 1.43-1.30 (m, 4H). MW: 420.50. LCMS (ES). found 421.2[MH]⁺.

Example 11N-Hydroxy-7-((5-methoxypyridin-2-yl)(pyridin-2-yl)amino)heptanamide

7-[(5-Hydroxy-pyridin-2-yl)-pyridin-2-yl-amino]-heptanoic acid ethylester (II)

Pd(OH)₂ (42 mg, 0.06 mmol), 1,4-cyclohexadiene (0.112 mL, 1.2 mmol) andI (105 mg, 0.24 mmol, preparation of which is outlined above in Example10) were stirred in EtOH_(abs) (5 mL) at 80° C. for 3 h. The reactionmixture was then filtered through silica and subsequently evaporatedunder reduced pressure. The resulting residue was purified by silica gelcolumn chromatography eluting with hexane/EtOAc (60:40 to 40:60) tofurnish II as a colourless oil (75 mg, 91%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.17 (d, J=4.5 Hz, 1H), 7.96-7.92 (m,1H), 7.52-7.45 (m, 1H), 7.09-7.02 (m, 1H), 6.99 (d, J=8.5 Hz, 1H),6.75-6.69 (m, 2H), 4.12 (q, J=7.0 Hz, 2H), 3.95 (t, J=7.5 Hz, 2H), 2.26(t, J=7.5 Hz, 2H), 1.66 (quin, J=7.5 Hz, 2H), 1.58 (quin, J=7.5 Hz, 2H),1.39-1.28 (m, 4H), 1.25 (t, J=7.3 Hz, 3H). MW: 343.42. LCMS (ES). found344.1 [MH]⁺.

7-[(5-Methoxy-pyridin-2-yl)-pyridin-2-yl-amino]heptanoic acid ethylester (III)

K₂CO₃ (12 mg, 0.087 mmol) was added to compound II (20 mg, 0.058 mmol)in DMF (2 mL) at it under Ar(g). After 15 min CH₃I (0.004 mL, 0.058mmol) was added and the reaction was stirred at 50° C. for 3 h30. Brine(15 mL) and EtOAc (15 mL) were added, then the phases were separated,and the aqueous phase was extracted with EtOAc (2×5 mL). The organicphases were combined then dried over MgSO₄, filtered, and subsequentlyevaporated under reduced pressure. The resulting residue was purified bysilica gel column chromatography eluting with hexane/EtOAc (80:20 then70:30) to furnish III as a colourless oil (11.65 mg, 56%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.28 (d, J=4.5 Hz, 1H), 8.17 (d, J=2.5Hz, 1H), 7.52-7.44 (m, 1H), 7.26-7.22 (m, J=2.0 Hz, 1H), 7.15 (d, J=9.0Hz, 1H), 6.78-6.73 (m, 1H), 6.71 (d, J=8.5 Hz, 1H), 4.11 (q, J=7.0 Hz,2H), 3.89 (s, 3H), 2.26 (t, J=7.5 Hz, 2H), 1.70 (quin, J=7.5 Hz, 2H),1.60 (quin, J=7.5 Hz, 2H), 1.45-1.30 (m, 4H), 1.25 (t, J=7.3 Hz, 3H).MW: 357.45. LCMS (ES). found 358.1 [MH]⁺.

7-[(5-Methoxy-pyridin-2-yl)-pyridin-2-yl-amino]heptanoic acidhydroxyamide (IV)

HONH₂ (50% aqueous, 2 mL) was added to III (11.65 mg, 0.033 mmol) in DMF(0.5 mL) and MeOH (2 mL) at rt. The reaction mixture was stirred for 28h, after which the solvents were evaporated under reduced pressure. Theresulting residue was dissolved and co-evaporated with toluene (2×10 mL)then was purified by silica gel column chromatography eluting withCH₂Cl₂/MeOH (100:4 then 100:6) to furnish IV as a colourless oil (6.76mg, 60%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.23 (dd, J=1.8, 5.3 Hz, 1H), 8.13 (d,J=3.5 Hz, 1H), 7.45-7.37 (m, 1H), 7.23 (dd, J=3.0, 8.5 Hz, 1H), 7.12 (d,J=8.5 Hz, 1H), 6.74-6.66 (m, 2H), 4.05 (t, J=7.5 Hz, 2H), 3.87 (s, 3H),2.12 (t, J=7.0 Hz, 2H), 1.69-1.54 (m, 4H), 1.39-1.30 (m, J=3.5 Hz, 4H).MW: 344.41. LCMS (ES). found 345.1 [MH]⁺.

Example 12N-Hydroxy-7-((5-phenylpyridin-2-yl)(pyridin-2-yl)amino)heptanamide

7-[Pyridin-2-yl-(5-trifluoromethanesulfonyloxy-pyridin-2-yl)-amino]-heptanoicacid ethyl ester (II)

TEA (27 μL, 0.2 mmol) and N-phenyl-bis(trifluoromethanesulfonimide) (50mg, 0.14 mmol) were added to I (44 mg, 0.13 mmol, preparation of whichis outlined above in Example 11) in CH₂Cl₂ (2 mL) at rt under Ar(g).After 17 h stirring, the reaction mixture was evaporated under reducedpressure and the resulting residue was purified by silica gel columnchromatography eluting with hexane/EtOAc (95:5 to 75:25) to furnish IIas a colourless oil (53 mg, 86%).

¹H NMR (300 MHz, CDCl₃) δ_(H): 8.44-8.39 (m, 1H), 8.23 (d, J=2.9 Hz,1H), 7.70-7.62 (m, 1H), 7.40-7.32 (m, 1H), 7.18 (d, J=8.1 Hz, 1H),7.07-6.99 (m, 2H), 4.20-4.04 (m, 4H), 2.28 (t, J=7.3 Hz, 2H), 1.75-1.54(m, 4H), 1.36 (td, J=3.5, 7.2 Hz, 4H), 1.25 (t, J=7.1 Hz, 3H). ¹⁹F NMR(282 MHz, CDCl₃)=−72.7. MW: 475.48. LCMS (ES). found 476.1 [MH]⁺.

7-[(5-Phenyl-pyridin-2-yl)-pyridin-2-yl-amino]-heptanoic acid ethylester (III)

Compound II (22 mg, 0.046 mmol), Pd(PPh₃)₄ (1.6 mg, 0.0014 mmol),phenylboronic acid (11.2 mg, 0.092 mmol) and potassium carbonate (9.5mg, 0.07 mmol) were stirred in toluene (2 mL) at 90° C. in a sealed tubefor 20 h. Then the reaction mixture was filtrated through celite andevaporated under reduced pressure. The resulting residue was purified bysilica gel column chromatography eluting with hexane/EtOAc (90:10 to70:30) to furnish 16 mg of III in mixture with the starting material.

MW: 403.52. LCMS (ES). found 404.2 [MH]⁺.

7-[(5-Phenyl-pyridin-2-yl)-pyridin-2-yl-amino]-heptanoic acidhydroxyamide (IV)

HONH₂ (50% aqueous, 2 mL) was added the crude batch of III (16 mg) inDMF (0.5 mL) and MeOH (2 mL) at rt. The reaction mixture was stirred for72 h, after which the solvents were evaporated under reduced pressure.The resulting residue was dissolved and co-evaporated with toluene (2×3mL) then was purified by silica gel column chromatography eluting withCH₂Cl₂/MeOH (100:8 then 100:10) to furnish IV as a colourless oil (1.36mg, 7% over two steps).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.61 (d, J=2.0 Hz, 1H), 8.39 (d, J=4.0Hz, 1H), 7.80 (dd, J=2.0, 8.5 Hz, 1H), 7.65-7.53 (m, 3H), 7.47 (t, J=7.5Hz, 2H), 7.41-7.33 (m, 1H), 7.15 (d, J=8.5 Hz, 1H), 7.12 (d, J=8.5 Hz,1H), 6.97-6.90 (m, 1H), 4.23 (t, J=7.5 Hz, 2H), 2.24-2.15 (m, 2H),1.79-1.70 (m, 2H), 1.69-1.62 (m, 2H), 1.48-1.31 (m, 4H). MW: 390.48.LCMS (ES). found 391.1 [MH]⁺.

Example 137-((5-(4-Fluorophenyl)pyridin-2-yl)(pyridin-2-yl)amino)-N-hydroxyheptanamide

7-{[5-(4-Fluoro-phenyl)-pyridin-2-yl]-pyridin-2-yl-amino}-heptanoic acidethyl ester (II)

Compound I (13 mg, 0.027 mmol, preparation of which is outlined above inExample 12), Pd(PPh₃)₄ (3.5 mg, 0.003 mmol), 4-fluorophenylboronic acid(7.6 mg, 0.055 mmol) and potassium carbonate (15 mg, 0.108 mmol) werestirred in toluene (1.5 mL) and water (0.7 mL) at 120° C. undermicrowave irradiation (300 W) for 20 min. The reaction mixture was thenpoured onto brine (5 mL) and extracted with EtOAc (3×5 mL). The organicphases were combined then dried over MgSO₄, filtered, and subsequentlyevaporated under reduced pressure. The resulting residue was purified bysilica gel column chromatography eluting with hexane/EtOAc (90:10 then85:15) to furnish II as a colourless oil (2.5 mg, 22%).

¹H NMR (300 MHz, CDCl₃) δ_(H): 8.54 (d, J=2.2 Hz, 1H), 8.38 (dd, J=1.3,4.9 Hz, 1H), 7.70 (dd, J=2.4, 8.6 Hz, 1H), 7.62-7.45 (m, 3H), 7.20-7.07(m, 4H), 6.91 (dd, J=5.3, 6.8 Hz, 1H), 4.27-4.19 (m, 2H), 4.12 (q, J=7.3Hz, 2H), 2.28 (t, J=7.5 Hz, 2H), 1.80-1.68 (m, 2H), 1.68-1.56 (m, 2H),1.46-1.31 (m, 4H), 1.25 (t, J=7.1 Hz, 3H). ¹⁹F NMR (282 MHz, CDCl₃) ¹⁹_(F)=−115.7. MW: 421.51. LCMS (ES). found 422.2 [MH]⁺.

7-((5-(4-Fluorophenyl)pyridin-2-yl)(pyridin-2-yl)-amino)-N-hydroxyheptanamide(III)

HONH₂ (50% aqueous, 0.5 mL) was added to II (2.5 mg, 0.006 mmol) in DMF(0.2 mL) and MeOH (0.5 mL) at rt. The reaction mixture was stirred for72 h, after which the solvents were evaporated under reduced pressure.The resulting residue was dissolved and co-evaporated with toluene (2×2mL) then was purified by silica gel column chromatography eluting withCH₂Cl₂/MeOH (100:6) to furnish III as a colourless oil (1.63 mg, 70%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.56 (d, J=2.5 Hz, 1H), 8.41-8.36 (m,1H), 7.74 (d, J=8.0 Hz, 1H), 7.62 (t, J=6.3 Hz, 1H), 7.53 (dd, J=5.3,8.3 Hz, 2H), 7.19-7.08 (m, 4H), 6.98-6.92 (m, J=4.0 Hz, 1H), 4.23 (t,J=7.0 Hz, 2H), 2.23-2.11 (m, 2H), 1.82-1.59 (m, 4H), 1.47-1.29 (m, 4H).MW: 408.47. LCMS (ES). found 409.2 [MH]⁺.

Example 14 7-(Isoquinolin-3-yl-pyridin-2-yl-amino)-heptanoic acidhydroxyamide

Isoquinolin-3-yl-pyridin-2-yl-amine (I)

2-Amino-isoquinoline (301 mg, 2.09 mmol), 2-bromopyridine (181 μL, 1.90mmol), tBuOK (320 mg, 2.55 mmol), (±)-BINAP (47 mg, 0.08 mmol) andPd₂(dba)₃ (43 mg, 0.05 mmol) were stirred in toluene (3 mL) at 90° C.under Ar(g) for 17 h. The reaction mixture was then diluted with CH₂Cl₂(5 mL) and silica was added followed by the removal of the solvent underreduced pressure. The resulting dry loaded material was purified bysilica gel column chromatography eluting with hexane/EtOAc (80:20 then70:30) to furnish I as a white solid (252 mg, 60%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.99 (s, 1H), 8.34 (d, J=4.0 Hz, 1H),8.28 (s, 1H), 7.87 (d, J=8.5 Hz, 1H), 7.78 (d, J=8.5 Hz, 1H), 7.67-7.55(m, 2H), 7.39 (t, J=7.5 Hz, 1H), 7.19 (d, J=7.5 Hz, 1H), 6.91-6.84 (m,1H). MW: 221.26. LCMS (ES). found 222.1 [MH]⁺.

7-(Isoquinolin-3-yl-pyridin-2-yl-amino)-heptanoic acid ethyl ester (II)

NaH (44 mg, 1.13 mmol) was added to I (250 mg, 1.13 mmol) in DMF (6 mL)at rt. After 10 min, KI (282 mg, 1.70 mmol) and ethyl 7-bromoheptanoate(0.330 mL, 1.70 mmol) were added. The reaction mixture was stirred at90° C. for 18 h after which 0.1 M Na₂S₂O₃ (50 mL) and EtOAc (50 mL) wereadded, the phases were separated and the aqueous extracted with EtOAc(50 mL). The organic phases were combined then dried over MgSO₄,filtered, and subsequently evaporated under reduced pressure. Theresulting residue was purified by silica gel column chromatographyeluting with hexane/EtOAc (90:10 then 80:20) to furnish II as acolourless oil (221 mg, 52%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 9.13 (s, 1H), 8.36-8.29 (m, 1H), 7.92 (d,J=8.0 Hz, 1H), 7.71-7.65 (m, 1H), 7.61 (t, J=7.3 Hz, 1H), 7.51-7.39 (m,3H), 6.93 (d, J=8.5 Hz, 1H), 6.77 (dd, J=5.5, 6.5 Hz, 1H), 4.25 (t,J=7.5 Hz, 2H), 4.11 (q, J=7.0 Hz, 2H), 2.26 (t, J=7.5 Hz, 2H), 1.79-1.71(m, 2H), 1.66-1.52 (m, 2H), 1.46-1.30 (m, 4H), 1.24 (t, J=7.3 Hz, 3H).MW: 377.48. LCMS (ES). found 378.2 [MH]⁺.

7-(Isoquinolin-3-yl-pyridin-2-yl-amino)-heptanoic acid hydroxyamide(III)

HONH₂ (50% aqueous, 1 mL) was added to II (40 mg, 0.1 mmol) in DMF (0.5mL) and MeOH (1 mL) at rt. The reaction mixture was stirred for 72 h,after which the solvents were evaporated under reduced pressure. Theresulting residue was dissolved and co-evaporated with toluene (2×2 mL)then was purified by silica gel column chromatography eluting withCH₂Cl₂/MeOH (100:3 to 100:8) to furnish III as a colourless oil (19 mg,54%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 9.15 (s, 1H), 8.32 (d, J=4.5 Hz, 1H),7.95 (d, J=8.0 Hz, 1H), 7.72 (d, J=8.5 Hz, 1H), 7.65 (t, J=7.5 Hz, 1H),7.54-7.42 (m, 3H), 6.85 (d, J=8.5 Hz, 1H), 6.80 (dd, J=5.5, 7.0 Hz, 1H),4.24 (t, J=7.5 Hz, 2H), 2.16 (t, J=6.8 Hz, 2H), 1.73 (quin, J=7.0 Hz,2H), 1.64 (quin, J=6.0 Hz, 2H), 1.47-1.29 (m, 4H). MW: 364.44. LCMS(ES). found 365.1 [MH]⁺.

Example 15 7-[(4-Benzyloxy-pyridin-2-yl)-pyridin-2-yl-amino]-heptanoicacid hydroxyamide

4-Benzyloxy-2-bromo-pyridine (I)

NaH (761 mg, 19.83 mmol) was added portion wise to2-bromo-4-hydroxypyridine (3 g, 17.24 mmol) in DMF (50 mL) at 0° C.under Ar(g). Then the reaction mixture was stirred at rt for 10 minafter which it was again cooled down at 0° C. and benzyl bromide (2.15mL, 18.10 mmol) was added. The reaction was stirred at it for 4 h, afterwhich it was poured onto brine (200 mL) and EtOAc (200 mL) was added.The phases were separated and the organic phase was dried over MgSO₄,filtered and subsequently evaporated under reduced pressure. Theresulting residue was purified by silica gel column chromatographyeluting with hexane/EtOAc (90:10 to 80:20) to furnish I as a white solid(2.331 g, 51%).

¹H NMR (400 MHz, CDCl₃) δ_(H), 8.05 (d, J=6.0 Hz, 1H), 7.31-7.20 (m,4H), 7.13 (s, 1H), 6.95 (d, J=2.5 Hz, 1H), 6.71 (dd, J=2.5, 6.0 Hz, 1H),4.97 (s, 2H). MW: 264.12. LCMS (ES). found 265.9 [MH]⁺.

(4-Benzyloxy-pyridin-2-yl)-pyridin-2-yl-amine (II)

Compound I (2.325 mg, 8.80 mmol), 2-aminopyridine (911 mg, 9.68 mmol),tBuOK (1.481 g, 13.20 mmol), (±)-BINAP (219 mg, 0.35 mmol) and Pd₂(dba)₃(201 mg, 0.22 mmol) were stirred in toluene (35 mL) at 90° C. underAr(g) for 17 h. The reaction mixture was then diluted with CH₂Cl₂ (20mL) and silica was added followed by the removal of the solvent underreduced pressure. The resulting dry loaded material was purified bysilica gel column chromatography eluting with hexane/EtOAc (60:40 then50:50) to furnish II as a yellow oil (1.773 g, 73%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.26 (dd, J=1.5, 5.0 Hz, 1H), 8.08-7.96(m, 1H), 7.61 (t, J=6.8 Hz, 1H), 7.51-7.32 (m, 7H), 6.88 (t, J=5.5 Hz,1H), 6.54 (dd, J=2.0, 6.0 Hz, 1H), 5.17 (s, 2H). MW: 277.32. LCMS (ES).found 278.1 [MH]⁺.

7-[(4-Benzyloxy-pyridin-2-yl)-pyridin-2-yl-amino]heptanoic acid ethylester (III)

NaH (245 mg, 6.38 mmol) was added to II (1.77 g, 6.38 mmol) in DMF (25mL) at rt. After 15 min, KI (1.588 g, 9.57 mmol) and ethyl7-bromoheptanoate (1.86 mL, 9.57 mmol) were added, and the reactionmixture was stirred at 90° C. for 17 h. Aqueous 0.1M Na₂S₂O₃ (100 mL)and EtOAc (100 mL) were added and the phases were separated. The organicphase was washed with brine (100 mL), dried over MgSO₄, filtered, andsubsequently evaporated under reduced pressure. The resulting residuewas purified by silica gel column chromatography eluting withhexane/EtOAc (90:10 to 70:30) to furnish III as a yellow oil (1.321 g,48%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.34 (dd, J=2.0, 5.0 Hz, 1H), 8.18 (d,J=6.0 Hz, 1H), 7.49-7.43 (m, 1H), 7.42-7.31 (m, 5H), 7.01 (d, J=8.5 Hz,1H), 6.84 (dd, J=5.3, 6.8 Hz, 1H), 6.60 (d, J=2.0 Hz, 1H), 6.53 (dd,J=2.3, 5.8 Hz, 1H), 5.04 (s, 2H), 4.18-4.05 (m, 4H), 2.26 (t, J=7.5 Hz,2H), 1.72-1.55 (m, 4H), 1.41-1.30 (m, 4H), 1.25 (t, J=7.0 Hz, 3H). MW:433.54. LCMS (ES). found 434.2 [MH]⁺.

7-[(4-Benzyloxy-pyridin-2-yl)-pyridin-2-yl-amino]-heptanoic acidhydroxyamide (IV)

HONH₂ (50% aqueous, 1 mL) was added to III (47 mg, 0.11 mmol) in DMF(0.2 mL) and MeOH (0.5 mL) at rt. The reaction mixture was stirred for72 h, after which the solvents were evaporated under reduced pressure.The resulting residue was dissolved and co-evaporated with toluene (2×2mL) then was purified by silica gel column chromatography eluting withCH₂Cl₂/MeOH (100:5) to furnish IV as a colourless oil (19 mg, 41%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.35 (dd, J=1.5, 5.0 Hz, 1H), 8.18 (d,J=5.5 Hz, 1H), 7.53-7.45 (m, 1H), 7.42-7.30 (m, 5H), 6.99 (d, J=8.5 Hz,1H), 6.89 (dd, J=5.0, 7.0 Hz, 1H), 6.57 (dd, J=2.3, 5.8 Hz, 1H), 6.54(d, J=2.0 Hz, 1H), 5.04 (s, 2H), 4.12 (t, J=7.5 Hz, 2H), 2.14 (t, J=6.8Hz, 2H), 1.70-1.59 (m, 4H), 1.41-1.26 (m, 4H). MW: 420.50. LCMS (ES).found 421.2 [MH]⁺.

Example 16 7-[(4-Methoxy-pyridin-2-yl)-pyridin-2-yl-amino]-heptanoicacid hydroxyamide

7-[(4-Hydroxy-pyridin-2-yl)-pyridin-2-yl-amino]-heptanoic acid ethylester (II)

Pd(OH)₂ (515 mg, 0.72 mmol), 1,4-cyclohexadiene (1.37 mL, 14.69 mmol)and compound I (1.274 g, 2.94 mmol, prepared using the method outlinedabove in Example 15) were stirred in EtOH_(abs) (25 mL) at 80° C. for2.5 h. Then the reaction mixture was filtered through silica andsubsequently evaporated under reduced pressure. The resulting residuewas purified by silica gel column chromatography eluting withCH₂Cl₂/MeOH (100:3 to 100:10) to furnish II as a colourless oil (728 mg,72%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.30 (dd, J=1.5, 5.0 Hz, 1H), 7.75-7.67(m, 1H), 7.59 (d, J=7.0 Hz, 1H), 7.03 (d, J=8.5 Hz, 1H), 6.98 (dd,J=5.3, 6.8 Hz, 1H), 6.40 (dd, J=2.0, 6.5 Hz, 1H), 6.28 (s, 1H), 4.13 (q,J=7.2 Hz, 2H), 3.89 (t, J=7.5 Hz, 2H), 2.30 (t, J=7.5 Hz, 2H), 1.79(quin, J=7.5 Hz, 2H), 1.64 (quin, J=7.2 Hz, 2H), 1.46-1.32 (m, 4H), 1.27(t, J=7.5 Hz, 3H). MW: 343.42. LCMS (ES). found 344.1 [MH]⁺.

7-[(4-Methoxy-pyridin-2-yl)-pyridin-2-yl-amino]-heptanoic acid ethylester (III)

K₂CO₃ (15 mg, 0.11 mmol) was added to II (25 mg, 0.073 mmol) in DMF (2mL) at rt under Ar(g). After 15 min CH₃I (5 μL, 0.073 mmol) was addedand the reaction was stirred at 70° C. for 22 h. Brine (30 mL) and EtOAc(30 mL) were added, then the phases were separated, and the aqueousphase was extracted with EtOAc (2×20 mL). The organic phases werecombined then dried over MgSO₄, filtered, and subsequently evaporatedunder reduced pressure. The resulting residue was purified by silica gelcolumn chromatography eluting with hexane/EtOAc (60:40) to furnish IIIas a colourless oil (10 mg, 40%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.37 (d, J=3.5 Hz, 1H), 8.20 (d, J=6.0Hz, 1H), 7.54 (t, J=7.3 Hz, 1H), 7.10 (d, J=8.5 Hz, 1H), 6.93-6.84 (m,1H), 6.53 (s, 1H), 6.48 (dd, J=2.3, 5.8 Hz, 1H), 4.17 (t, J=7.5 Hz, 2H),4.12 (q, J=7.0 Hz, 2H), 3.79 (s, 3H), 2.27 (t, J=7.5 Hz, 2H), 1.70(quin, J=7.5 Hz, 2H), 1.60 (quin, J=7.5 Hz, 2H), 1.42-1.31 (m, 4H), 1.25(t, J=7.0 Hz, 3H). MW: 357.45. LCMS (ES). found 358.2 [MH]⁺.

7-[(4-Methoxy-pyridin-2-yl)-pyridin-2-yl-amino]heptanoic acidhydroxyamide (IV)

HONH₂ (50% aqueous, 2 mL) was added to III (10 mg, 0.028 mmol) in DMF(0.5 mL) and MeOH (2 mL) at rt. The reaction mixture was stirred for 17h, after which the solvents were evaporated under reduced pressure. Theresulting residue was dissolved and co-evaporated with toluene (2×2 mL)then was purified by silica gel column chromatography eluting withCH₂Cl₂/MeOH (100:3 to 100:10) to furnish IV as a colourless oil (8 mg,84%).

¹H NMR (400 MHz, MeOD) δ_(H): 8.26 (dd, J=2.0, 5.0 Hz, 1H), 8.09 (d,J=6.0 Hz, 1H), 7.68-7.62 (m, 1H), 7.05 (d, J=8.0 Hz, 1H), 6.98-6.92 (m,1H), 6.65 (dd, J=2.5, 6.0 Hz, 1H), 6.58 (d, J=2.0 Hz, 1H), 4.07 (t,J=7.5 Hz, 2H), 3.82 (s, 3H), 2.06 (t, J=7.0 Hz, 2H), 1.66 (quin, J=8.0Hz, 2H), 1.57 (quin, J=7.0 Hz, 2H), 1.41-1.30 (m, 4H). MW: 344.41. LCMS(ES). found 345.1 [MH]⁺.

Example 17 7-[(4-Ethoxy-pyridin-2-yl)-pyridin-2-yl-amino]-heptanoic acidhydroxyamide

7-[(4-Hydroxy-pyridin-2-yl)-pyridin-2-yl-amino]-heptanoic acid ethylester (II)

Pd(OH)₂ (515 mg, 0.72 mmol), 1,4-cyclohexadiene (1.37 mL, 14.69 mmol)and compound I (1.274 g, 2.94 mmol, prepared using the method outlinedabove in Example 15) were stirred in EtOH_(abs) (25 mL) at 80° C. for2.5 h. Then the reaction mixture was filtered through silica andsubsequently evaporated under reduced pressure. The resulting residuewas purified by silica gel column chromatography eluting withCH₂Cl₂/MeOH (100:3 to 100:10) to furnish II as a colourless oil (728 mg,72%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.30 (dd, J=1.5, 5.0 Hz, 1H), 7.75-7.67(m, 1H), 7.59 (d, J=7.0 Hz, 1H), 7.03 (d, J=8.5 Hz, 1H), 6.98 (dd,J=5.3, 6.8 Hz, 1H), 6.40 (dd, J=2.0, 6.5 Hz, 1H), 6.28 (s, 1H), 4.13 (q,J=7.2 Hz, 2H), 3.89 (t, J=7.5 Hz, 2H), 2.30 (t, J=7.5 Hz, 2H), 1.79(quin, J=7.5 Hz, 2H), 1.64 (quin, J=7.2 Hz, 2H), 1.46-1.32 (m, 4H), 1.27(t, J=7.5 Hz, 3H). MW: 343.42. LCMS (ES). found 344.1 [MH]⁺.

7-[(4-Ethoxy-pyridin-2-yl)-pyridin-2-yl-amino]heptanoic acid ethyl ester(III)

K₂CO₃ (21 mg, 0.15 mmol) was added to II (31 mg, 0.10 mmol) in DMF (2mL) at it under Ar(g). After 15 min iodoethane (9 μL, 0.11 mmol) wasadded and the reaction was stirred at 70° C. for 26 h. Brine (50 mL) andEtOAc (25 mL) were added, then the phases were separated, and theaqueous phase was extracted with EtOAc (25 mL). The organic phases werecombined then dried over MgSO₄, filtered, and subsequently evaporatedunder reduced pressure. The resulting residue was purified by silica gelcolumn chromatography eluting with hexane/EtOAc (60:40) to furnish IIIas a colourless oil (16 mg, 43%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.34 (dd, J=1.8, 5.3 Hz, 1H), 8.17 (d,J=5.5 Hz, 1H), 7.55-7.43 (m, 1H), 7.07 (d, J=8.5 Hz, 1H), 6.84 (dd,J=4.8, 7.3 Hz, 1H), 6.54 (d, J=2.0 Hz, 1H), 6.45 (dd, J=2.3, 5.8 Hz,1H), 4.14 (t, J=7.5 Hz, 2H), 4.12 (q, J=7.0 Hz, 2H), 4.01 (q, J=7.0 Hz,2H), 2.26 (t, J=7.5 Hz, 2H), 1.69 (quin, J=7.5 Hz, 2H), 1.60 (quin,J=7.3 Hz, 2H), 1.41 (t, J=7.0 Hz, 3H), 1.37-1.30 (m, 4H), 1.25 (t, J=7.3Hz, 3H). MW: 371.47. LCMS (ES). found 372.2 [MH]⁺.

7-[(4-Ethoxy-pyridin-2-yl)-pyridin-2-yl-amino]-heptanoic acidhydroxyamide (IV)

HONH₂ (50% aqueous, 2 mL) was added to III (16 mg, 0.045 mmol) in DMF(0.5 mL) and MeOH (2 mL) at rt. The reaction mixture was stirred for 17h, after which the solvents were evaporated under reduced pressure. Theresulting residue was dissolved and co-evaporated with toluene (2×2 mL)then was purified by silica gel column chromatography eluting withCH₂Cl₂/MeOH (100:3 to 100:8) to furnish IV as a colourless oil (12 mg,75%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.33 (dd, J=1.8, 5.3 Hz, 1H), 8.16 (d,J=6.0 Hz, 1H), 7.55-7.47 (m, 1H), 7.02 (d, J=8.0 Hz, 1H), 6.85 (dd,J=5.0, 6.5 Hz, 1H), 6.51 (d, J=2.0 Hz, 1H), 6.48 (dd, J=2.0, 5.5 Hz,1H), 4.10 (t, J=7.5 Hz, 2H), 4.01 (q, J=7.0 Hz, 2H), 2.10 (t, J=6.8 Hz,2H), 1.72-1.53 (m, 4H), 1.40 (t, J=7.0 Hz, 3H), 1.36-1.25 (m, 4H). MW:358.43. LCMS (ES). found 359.1 [MH]⁺.

Example 18 7-[(4-Propoxy-pyridin-2-yl)-pyridin-2-yl-amino]heptanoic acidhydroxyamide

7-[(4-Hydroxy-pyridin-2-yl)-pyridin-2-yl-amino]heptanoic acid ethylester (II)

Pd(OH)₂ (515 mg, 0.72 mmol), 1,4-cyclohexadiene (1.37 mL, 14.69 mmol)and I (1.274 g, 2.94 mmol, prepared using the method outlined above inExample 15) were stirred in EtOH_(abs) (25 mL) at 80° C. for 2.5 h. Thenthe reaction mixture was filtered through silica and subsequentlyevaporated under reduced pressure. The resulting residue was purified bysilica gel column chromatography eluting with CH₂Cl₂/MeOH (100:3 to100:10) to furnish II as a colourless oil (728 mg, 72%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.30 (dd, J=1.5, 5.0 Hz, 1H), 7.75-7.67(m, 1H), 7.59 (d, J=7.0 Hz, 1H), 7.03 (d, J=8.5 Hz, 1H), 6.98 (dd,J=5.3, 6.8 Hz, 1H), 6.40 (dd, J=2.0, 6.5 Hz, 1H), 6.28 (s, 1H), 4.13 (q,J=7.2 Hz, 2H), 3.89 (t, J=7.5 Hz, 2H), 2.30 (t, J=7.5 Hz, 2H), 1.79(quin, J=7.5 Hz, 2H), 1.64 (quin, J=7.2 Hz, 2H), 1.46-1.32 (m, 4H), 1.27(t, J=7.5 Hz, 3H). MW: 343.42. LCMS (ES). found 344.1 [MH]⁺.

7-[(4-Propoxy-pyridin-2-yl)-pyridin-2-yl-amino]heptanoic acid ethylester (III)

K₂CO₃ (21 mg, 0.15 mmol) was added to II (31 mg, 0.10 mmol) in DMF (2mL) at rt under Ar(g). After 15 min iodopropane (11 μL, 0.11 mmol) wasadded and the reaction was stirred at 70° C. for 17 h. Brine (50 mL) andEtOAc (25 mL) were added, then the phases were separated, and theaqueous phase was extracted with EtOAc (25 mL). The organic phases werecombined then dried over MgSO₄, filtered, and subsequently evaporatedunder reduced pressure. The resulting residue was purified by silica gelcolumn chromatography eluting with hexane/EtOAc (70:30) to furnish IIIas a colourless oil (28 mg, 80%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.35 (dd, J=1.5, 5.0 Hz, 1H), 8.17 (d,J=5.5 Hz, 1H), 7.55-7.46 (m, 1H), 7.07 (d, J=8.0 Hz, 1H), 6.85 (t, J=6.5Hz, 1H), 6.54 (d, J=2.0 Hz, 1H), 6.47 (dd, J=2.0, 6.0 Hz, 1H), 4.15 (t,J=7.5 Hz, 2H), 4.11 (q, J=7.0 Hz, 2H), 3.90 (t, J=6.5 Hz, 2H), 2.26 (t,J=7.8 Hz, 2H), 1.79 (sxt, J=7.0 Hz, 2H), 1.69 (quin, J=7.4 Hz, 2H), 1.60(quin, J=7.4 Hz, 2H), 1.43-1.29 (m, 4H), 1.26 (t, J=7.0 Hz, 3H), 1.02(t, J=7.3 Hz, 3H). MW: 385.50. LCMS (ES). found 386.2 [MH]⁺.

7-[(4-Propoxy-pyridin-2-yl)-pyridin-2-yl-amino]heptanoic acidhydroxyamide (IV)

HONH₂ (50% aqueous, 2 mL) was added to III (16 mg, 0.045 mmol) in DMF(0.5 mL) and MeOH (2 mL) at rt. The reaction mixture was stirred for22.5 h, after which the solvents were evaporated under reduced pressure.The resulting residue was dissolved and co-evaporated with toluene (2×2mL) then was purified by silica gel column chromatography eluting withCH₂Cl₂/MeOH (100:5 to 100:8) to furnish IV as a colourless oil (14 mg,50%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.36 (d, J=3.0 Hz, 1H), 8.18 (d, J=3.5Hz, 1H), 7.54 (t, J=7.8 Hz, 1H), 7.04 (d, J=8.5 Hz, 1H), 6.89 (t, J=5.8Hz, 1H), 6.50 (br. s., 2H), 4.14 (t, J=6.3 Hz, 2H), 3.90 (t, J=6.5 Hz,2H), 2.15 (br. s., 2H), 1.79 (sxt, J=6.9 Hz, 2H), 1.71-1.57 (m, 4H),1.36 (br. s., 4H), 1.02 (t, J=7.3 Hz, 3H). MW: 372.46. LCMS (ES). found373.2 [MH]⁺.

Example 19 7-[(4-Isopropoxy-pyridin-2-yl)-pyridin-2-yl-amino]-heptanoicacid hydroxyamide

7-[(4-Hydroxy-pyridin-2-yl)-pyridin-2-yl-amino]-heptanoic acid ethylester (II)

Pd(OH)₂ (515 mg, 0.72 mmol), 1,4-cyclohexadiene (1.37 mL, 14.69 mmol)and compound I (1.274 g, 2.94 mmol, prepared using the method outlinedabove in Example 15) were stirred in EtOH_(abs) (25 mL) at 80° C. for2.5 h. Then the reaction mixture was filtered through silica andsubsequently evaporated under reduced pressure. The resulting residuewas purified by silica gel column chromatography eluting withCH₂Cl₂/MeOH (100:3 to 100:10) to furnish II as a colourless oil (728 mg,72%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.30 (dd, J=1.5, 5.0 Hz, 1H), 7.75-7.67(m, 1H), 7.59 (d, J=7.0 Hz, 1H), 7.03 (d, J=8.5 Hz, 1H), 6.98 (dd,J=5.3, 6.8 Hz, 1H), 6.40 (dd, J=2.0, 6.5 Hz, 1H), 6.28 (s, 1H), 4.13 (q,J=7.2 Hz, 2H), 3.89 (t, J=7.5 Hz, 2H), 2.30 (t, J=7.5 Hz, 2H), 1.79(quin, J=7.5 Hz, 2H), 1.64 (quin, J=7.2 Hz, 2H), 1.46-1.32 (m, 4H), 1.27(t, J=7.5 Hz, 3H). MW: 343.42. LCMS (ES). found 344.1 [MH]⁺.

7[(4-Isopropoxy-pyridin-2-yl)-pyridin-2-yl-amino]-heptanoic acid ethylester (III)

K₂CO₃ (32 mg, 0.23 mmol) was added to II (53 mg, 0.15 mmol) in DMF (2mL) at it under Ar(g). After 15 min 2-iodopropane (16 μL, 0.165 mmol)was added and the reaction was stirred at 70° C. for 3 h. Brine (50 mL)and EtOAc (25 mL) were added, then the phases were separated, and theaqueous phase was extracted with EtOAc (25 mL). The organic phases werecombined then dried over MgSO₄, filtered, and subsequently evaporatedunder reduced pressure. The resulting residue was purified by silica gelcolumn chromatography eluting with hexane/EtOAc (70:30) to furnish IIIas a colourless oil (23 mg, 40%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.34 (dd, J=2.0, 5.0 Hz, 1H), 8.16 (d,J=6.0 Hz, 1H), 7.54-7.47 (m, 1H), 7.06 (d, J=8.0 Hz, 1H), 6.83 (dd,J=5.3, 6.8 Hz, 1H), 6.51 (d, J=2.0 Hz, 1H), 6.44 (dd, J=2.0, 6.0 Hz,1H), 4.53 (spt, J=6.1 Hz, 1H), 4.14 (t, J=7.5 Hz, 2H), 4.09 (q, J=7.5Hz, 2H), 2.26 (t, J=7.5 Hz, 2H), 1.69 (quin, J=7.4 Hz, 2H), 1.60 (quin,J=7.3 Hz, 2H), 1.38-1.34 (m, 4H), 1.34 (s, 3H), 1.32 (s, 3H), 1.25 (t,J=7.0 Hz, 3H). MW: 385.50. LCMS (ES). found 386.2 [MH]⁺.

7-[(4-Isopropoxy-pyridin-2-yl)-pyridin-2-yl-amino]heptanoic acidhydroxyamide (IV)

HONH₂ (50% aqueous, 2 mL) was added to III (23 mg, 0.06 mmol) in DMF(0.5 mL) and MeOH (2 mL) at rt. The reaction mixture was stirred for 26h, after which the solvents were evaporated under reduced pressure. Theresulting residue was dissolved and co-evaporated with toluene (2×2 mL)then was purified by silica gel column chromatography eluting withCH₂Cl₂/MeOH (100:5 to 100:8) to furnish IV as a colourless oil (14 mg,65%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.34 (dd, J=1.8, 5.3 Hz, 1H), 8.16 (d,J=6.5 Hz, 1H), 7.55-7.47 (m, 1H), 7.02 (d, J=8.5 Hz, 1H), 6.86 (dd,J=5.3, 6.8 Hz, 1H), 6.51-6.43 (m, 2H), 4.54 (spt, J=6.0 Hz, 1H), 4.11(t, J=7.5 Hz, 2H), 2.13 (t, J=6.5 Hz, 2H), 1.72-1.56 (m, 4H), 1.41-1.24(m, 10H). MW: 372.46. LCMS (ES). found 373.2 [MH]⁺.

Example 20 7-(Pyridin-3-yl-pyridin-2-yl-amino)-heptanoic acidhydroxyamide

Pyridin-3-yl-pyridin-2-yl-amine (I)

2-Bromopyridine (0.3 mL, 3.16 mmol), 3-aminopyridine (327 mg, 3.48mmol), tBuOK (532 mg, 4.74 mmol), (±)-BINAP (79 mg, 0.126 mmol) andPd₂(dba)₃ (72 mg, 0.079 mmol) were stirred in toluene (5 mL) at 90° C.under Ar(g) for 19 h. The reaction mixture was then diluted with CH₂Cl₂(5 mL) and silica was added followed by the removal of the solvent underreduced pressure. The resulting dry loaded material was purified bysilica gel column chromatography eluting with CH₂Cl₂/MeOH (100:3 to100:6) to furnish I as a brown oil (483 mg, 90%).

¹H NMR (400 MHz, MeOD) δ_(H): 8.76 (d, J=2.5 Hz, 1H), 8.20 (ddd, J=1.5,3.0, 8.5 Hz, 1H), 8.16 (td, J=1.2, 5.1 Hz, 1H), 8.06 (dd, J=1.5, 5.0 Hz,1H), 7.62-7.56 (m, 1H), 7.32 (dd, J=4.3, 8.8 Hz, 1H), 6.86-6.78 (m, 2H).MW: 171.20. LCMS (ES). found 172.1 [MH]⁺.

7-(Pyridin-3-yl-pyridin-2-yl-amino)-heptanoic acid ethyl ester (II)

NaH (107 mg, 2.8 mmol) was added to II (480 mg, 2.8 mmol) in DMF (10 mL)at rt. After 15 min, KI (697 mg, 4.2 mmol) and ethyl 7-bromoheptanoate(0.825 mL, 4.2 mmol) were added, and the reaction mixture was stirred at90° C. for 17 h. Aqueous 0.1M Na₂S₂O₃ (100 mL) and EtOAc (100 mL) wereadded and the phases were separated. The organic phase was washed withbrine (100 mL), dried over MgSO₄, filtered, and subsequently evaporatedunder reduced pressure. The resulting residue was purified by silica gelcolumn chromatography eluting with CH₂Cl₂/MeOH (100:1 to 100:3) tofurnish II as a brown oil (141 mg, 15%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.55 (br. s., 1H), 8.46 (br. s., 1H),8.22 (d, J=5.0 Hz, 1H), 7.59 (d, J=8.0 Hz, 1H), 7.42-7.31 (m, 2H), 6.68(t, J=5.8 Hz, 1H), 6.47 (d, J=8.0 Hz, 1H), 4.12 (q, J=7.0 Hz, 2H), 3.96(t, J=7.5 Hz, 2H), 2.27 (t, J=7.5 Hz, 2H), 1.72-1.55 (m, 4H), 1.42-1.30(m, 4H), 1.25 (t, J=7.0 Hz, 3H). MW: 327.42. LCMS (ES). found 328.2[MH]⁺.

7-(Pyridin-3-yl-pyridin-2-yl-amino)-heptanoic acid hydroxyamide (III)

HONH₂ (50% aqueous, 2 mL) was added to II (140 mg, 0.43 mmol) in DMF(0.5 mL) and MeOH (2 mL) at rt. The reaction mixture was stirred for 24h, after which the solvents were evaporated under reduced pressure. Theresulting residue was dissolved and co-evaporated with toluene (2×2 mL)then was purified by silica gel column chromatography eluting withCH₂Cl₂/MeOH (100:4 to 100:25) to furnish III as a yellow oil (31 mg,23%).

¹H NMR (400 MHz, MeOD) δ_(H): 8.44 (d, J=2.5 Hz, 1H), 8.36 (dd, J=1.5,5.0 Hz, 1H), 8.12 (ddd, J=1.0, 2.0, 5.0 Hz, 1H), 7.74 (ddd, J=1.5, 2.5,8.0 Hz, 1H), 7.54-7.46 (m, 2H), 6.75 (dd, J=5.0, 6.5 Hz, 1H), 6.62 (d,J=8.5 Hz, 1H), 3.94 (t, J=7.5 Hz, 2H), 2.06 (t, J=7.5 Hz, 2H), 1.72-1.54(m, 4H), 1.42-1.30 (m, 4H). MW: 314.38. LCMS (ES). found 315.1 [MH]⁺.

Example 217-{[4-(4-Fluoro-phenyl)-pyridin-2-yl]-pyridin-2-yl-amino}-heptanoic acidhydroxyamide

7-[(Pyridin-2-yl-(4-trifluoromethanesulfonyloxy-pyridin-2-yl)-amino]-heptanoicacid ethyl ester (II)

TEA (345 μL, 2.56 mmol) and N-phenyl-bis(trifluoromethanesulfonimide)(673 mg, 1.88 mmol) were added to I (588 mg, 1.71 mmol, prepared usingthe method outlined above in Example 16) in CH₂Cl₂ (10 mL) at rt underAr(g). After 27 h stirring, the reaction mixture was evaporated underreduced pressure and the resulting residue was purified by silica gelcolumn chromatography eluting with hexane/EtOAc (80:20) to furnish II asa colourless oil (653 mg, 80%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.43 (dd, J=2.0, 5.0 Hz, 1H), 8.33 (d,J=5.5 Hz, 1H), 7.71-7.61 (m, 1H), 7.20 (d, J=8.0 Hz, 1H), 7.05 (ddd,J=1.0, 5.0, 7.5 Hz, 1H), 6.87 (d, J=2.5 Hz, 1H), 6.68 (dd, J=2.0, 5.5Hz, 1H), 4.17 (t, J=7.5 Hz, 2H), 4.11 (q, J=7.5 Hz, 2H), 2.27 (t, J=7.5Hz, 2H), 1.80-1.54 (m, 4H), 1.44-1.32 (m, 4H), 1.25 (t, J=7.5 Hz, 3H).MW: 475.48. LCMS (ES). found 476.1 [MH]⁺.

7-{[4-(4-Fluoro-phenyl)-pyridin-2-yl]-pyridin-2-yl-amino}-heptanoic acidethyl ester (III)

Compound II (54 mg, 0.113 mmol), Pd(PPh₃)₄ (13 mg, 0.011 mmol),4-fluorophenylboronic acid (32 mg, 0.23 mmol) and potassium carbonate(63 mg, 0.45 mmol) were stirred in toluene (1.5 mL) and water (0.7 mL)at 120° C. under microwave irradiation (300 W) for 30 min. The reactionmixture was then poured onto brine (5 mL) and extracted with EtOAc (3×5mL). The organic phases were combined then dried over MgSO₄, filtered,and subsequently evaporated under reduced pressure. The resultingresidue was purified by silica gel column chromatography eluting withhexane/EtOAc (90:10 then 80:20) to furnish III as a colourless oil (34mg, 71%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.43-8.29 (m, 2H), 7.61-7.47 (m, 3H),7.22 (s, 1H), 7.17-7.08 (m, J=8.5, 8.5 Hz, 3H), 7.04 (d, J=4.5 Hz, 1H),6.89 (t, J=5.5 Hz, 1H), 4.23 (t, J=7.5 Hz, 2H), 4.11 (q, J=7.0 Hz, 2H),2.27 (t, J=7.5 Hz, 2H), 1.74 (quin, J=7.5 Hz, 2H), 1.62 (quin, J=7.3 Hz,2H), 1.46-1.30 (m, 4H), 1.24 (t, J=7.0 Hz, 3H). MW: 421.51. LCMS (ES).found 422.2 [MH]⁺.

7-{[4-(4-Fluoro-phenyl)-pyridin-2-yl]-pyridin-2-yl-amino}-heptanoic acidhydroxyamide (IV)

HONH₂ (50% aqueous, 2 mL) was added to III (34 mg, 0.08 mmol) in DMF(0.5 mL) and MeOH (2 mL) at rt. The reaction mixture was stirred for 23h, after which the solvents were evaporated under reduced pressure. Theresulting residue was dissolved and co-evaporated with toluene (2×2 mL)then was purified by silica gel column chromatography eluting withCH₂Cl₂/MeOH (100:3 to 100:6) to furnish IV as a colourless oil (18 mg,54%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.43-8.36 (m, 2H), 7.65-7.57 (m, 1H),7.56-7.49 (m, 2H), 7.21-7.07 (m, 5H), 6.95 (dd, J=5.3, 6.8 Hz, 1H), 4.22(t, J=7.5 Hz, 2H), 2.18 (t, J=6.8 Hz, 2H), 1.73 (quin, J=7.0 Hz, 2H),1.65 (quin, J=7.0 Hz, 2H), 1.47-1.31 (m, 4H). MW: 408.47. LCMS (ES).found 409.2 [MH]⁺.

Example 227-{([4-(4-Amino-phenyl)-pyridin-2-yl]-pyridin-2-yl-amino}-heptanoic acidhydroxyamide

7-[Pyridin-2-yl-(4-trifluoromethanesulfonyloxy-pyridin-2-yl)-amino]-heptanoicacid ethyl ester (II)

TEA (345 μL, 2.56 mmol) and N-phenyl-bis(trifluoromethanesulfonimide)(673 mg, 1.88 mmol) were added to I (588 mg, 1.71 mmol, prepared usingthe method outlined above in Example 16) in CH₂Cl₂ (10 mL) at rt underAr(g). After 27 h stirring, the reaction mixture was evaporated underreduced pressure and the resulting residue was purified by silica gelcolumn chromatography eluting with hexane/EtOAc (80:20) to furnish II asa colourless oil (653 mg, 80%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.43 (dd, J=2.0, 5.0 Hz, 1H), 8.33 (d,J=5.5 Hz, 1H), 7.71-7.61 (m, 1H), 7.20 (d, J=8.0 Hz, 1H), 7.05 (ddd,J=1.0, 5.0, 7.5 Hz, 1H), 6.87 (d, J=2.5 Hz, 1H), 6.68 (dd, J=2.0, 5.5Hz, 1H), 4.17 (t, J=7.5 Hz, 2H), 4.11 (q, J=7.5 Hz, 2H), 2.27 (t, J=7.5Hz, 2H), 1.80-1.54 (m, 4H), 1.44-1.32 (m, 4H), 1.25 (t, J=7.5 Hz, 3H).MW: 475.48. LCMS (ES). found 476.1 [MH]⁺.

7-{[4-(4-Amino-phenyl)-pyridin-2-yl]-pyridin-2-yl-amino}-heptanoic acidethyl ester (III)

Compound II (52 mg, 0.109 mmol), Pd(PPh₃)₄ (12 mg, 0.011 mmol),4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (48 mg, 0.218mmol) and potassium carbonate (60 mg, 0.44 mmol) were stirred in toluene(3 mL) and water (1.5 mL) at 120° C. under microwave irradiation (300 W)for 30 min. The reaction mixture was then poured onto brine (50 mL) andextracted with EtOAc (2×20 mL). The organic phases were combined thendried over MgSO₄, filtered, and subsequently evaporated under reducedpressure. The resulting residue was purified by silica gel columnchromatography eluting with hexane/EtOAc (90:10 then 0:100) to furnishIII as a brown oil (32 mg, 70%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.51-8.42 (m, 1H), 8.37 (d, J=5.5 Hz,1H), 7.72-7.57 (m, 1H), 7.51 (d, J=8.5 Hz, 1H), 7.45-7.35 (m, 2H),7.20-7.07 (m, 3H), 6.77-6.70 (m, 2H), 4.34-4.23 (m, 2H), 4.11 (q, J=7.0Hz, 2H), 2.27 (t, J=7.5 Hz, 2H), 1.83-1.72 (m, 2H), 1.65-1.58 (m, 2H),1.49-1.34 (m, 4H), 1.24 (t, J=7.0 Hz, 3H). MW: 418.53. LCMS (ES). found419.2 [MH]⁺.

7-{[4-(4-Amino-phenyl)-pyridin-2-yl]-pyridin-2-yl-amino}-heptanoic acidhydroxyamide (IV)

HONH₂ (50% aqueous, 2 mL) was added to III (30 mg, 0.072 mmol) in DMF(0.5 mL) and MeOH (2 mL) at rt. The reaction mixture was stirred for 22h, after which the solvents were evaporated under reduced pressure. Theresulting residue was dissolved and co-evaporated with toluene (2×2 mL)then was purified by silica gel column chromatography eluting withCH₂Cl₂/MeOH (100:10) to furnish IV as a yellow oil (7 mg, 24%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.45-8.33 (m, 2H), 7.65-7.57 (m, 1H),7.56-7.49 (m, 2H), 7.21-7.07 (m, 5H), 6.95 (dd, J=5.3, 6.8 Hz, 1H), 4.22(t, J=7.5 Hz, 2H), 2.18 (t, J=6.8 Hz, 2H), 1.73 (quin, J=7.5 Hz, 2H),1.65 (quin, J=7.0 Hz, 2H), 1.46-1.33 (m, 4H). MW: 405.49. LCMS (ES).found 406.2 [MH]⁺.

Example 23 7-[Pyridin-2-yl-(4-p-tolyl-pyridin-2-yl)-amino]-heptanoicacid hydroxyamide

7-[Pyridin-2-yl-(4-trifluoromethanesulfonyloxy-pyridin-2-yl)-amino]-heptanoicacid ethyl ester (II)

TEA (345 μL, 2.56 mmol) and N-phenyl-bis(trifluoromethanesulfonimide)(673 mg, 1.88 mmol) were added to I (588 mg, 1.71 mmol, prepared usingthe method outlined above in Example 16) in CH₂Cl₂ (10 mL) at it underAr(g). After 27 h stirring, the reaction mixture was evaporated underreduced pressure and the resulting residue was purified by silica gelcolumn chromatography eluting with hexane/EtOAc (80:20) to furnish II asa colourless oil (653 mg, 80%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.43 (dd, J=2.0, 5.0 Hz, 1H), 8.33 (d,J=5.5 Hz, 1H), 7.71-7.61 (m, 1H), 7.20 (d, J=8.0 Hz, 1H), 7.05 (ddd,J=1.0, 5.0, 7.5 Hz, 1H), 6.87 (d, J=2.5 Hz, 1H), 6.68 (dd, J=2.0, 5.5Hz, 1H), 4.17 (t, J=7.5 Hz, 2H), 4.11 (q, J=7.5 Hz, 2H), 2.27 (t, J=7.5Hz, 2H), 1.80-1.54 (m, 4H), 1.44-1.32 (m, 4H), 1.25 (t, J=7.5 Hz, 3H).MW: 475.48. LCMS (ES). found 476.1 [MH]⁺.

7-[Pyridin-2-yl-(4-p-tolyl-pyridin-2-yl)-amino]heptanoic acid ethylester (III)

Compound II (56 mg, 0.117 mmol), Pd(PPh₃)₄ (12 mg, 0.011 mmol),p-tolylboronic acid (32 mg, 0.235 mmol) and potassium carbonate (65 mg,0.47 mmol) were stirred in toluene (3 mL) and water (1.5 mL) at 120° C.under microwave irradiation (300 W) for 30 min. The reaction mixture wasthen poured onto brine (30 mL) and extracted with EtOAc (2×20 mL). Theorganic phases were combined then dried over MgSO₄, filtered, andsubsequently evaporated under reduced pressure. The resulting residuewas purified by silica gel column chromatography eluting withhexane/EtOAc (90:10 then 80:20) to furnish III as a colourless oil (43mg, 88%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.41-8.29 (m, 2H), 7.53 (t, J=7.3 Hz,1H), 7.49-7.42 (m, 2H), 7.30-7.19 (m, 3H), 7.15-7.04 (m, 2H), 6.92-6.82(m, 1H), 4.23 (t, J=7.5 Hz, 2H), 4.11 (q, J=7.0 Hz, 2H), 2.40 (s, 3H),2.27 (t, J=7.5 Hz, 2H), 1.75 (quin, J=7.4 Hz, 2H), 1.62 (quin, J=7.4 Hz,2H), 1.45-1.31 (m, 4H), 1.25 (t, J=7.0 Hz, 3H). MW: 417.54. LCMS (ES).found 418.2 [MH]⁺.

7-[Pyridin-2-yl-(4-p-tolyl-pyridin-2-yl)-amino]heptanoic acidhydroxyamide (IV)

HONH₂ (50% aqueous, 2 mL) was added to III (43 mg, 0.10 mmol) in DMF(0.5 mL) and MeOH (2 mL) at rt. The reaction mixture was stirred for 17h, after which the solvents were evaporated under reduced pressure. Theresulting residue was dissolved and co-evaporated with toluene (2×2 mL)then was purified by silica gel column chromatography eluting withCH₂Cl₂/MeOH (100:4 to 100:7) to furnish IV as a colourless oil (16 mg,38%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.43-8.31 (m, 2H), 7.57 (t, J=7.3 Hz,1H), 7.48-7.39 (m, 2H), 7.29-7.19 (m, 3H), 7.14 (d, J=4.5 Hz, 1H), 7.09(d, J=8.5 Hz, 1H), 6.92 (t, J=6.0 Hz, 1H), 4.21 (t, J=7.3 Hz, 2H), 2.40(s, 3H), 2.17 (t, J=6.3 Hz, 2H), 1.72 (quin, J=7.0 Hz, 2H), 1.65 (quin,J=6.5 Hz, 2H), 1.46-1.32 (m, 4H). MW: 404.50. LCMS (ES). found 405.2[MH]⁺.

Example 24 7-[Pyridin-2-yl-(4-o-tolyl-pyridin-2-yl)-amino]-heptanoicacid hydroxyamide

7-[Pyridin-2-yl-(4-o-tolyl-pyridin-2-yl)-amino]heptanoic acid ethylester (II)

Compound I (65 mg, 0.136 mmol, prepared using the method outlined abovefor Example 21), Pd(PPh₃)₄ (16 mg, 0.014 mmol), o-tolylboronic acid (37mg, 0.273 mmol) and potassium carbonate (75 mg, 0.54 mmol) were stirredin toluene (3 mL) and water (1.5 mL) at 120° C. under microwaveirradiation (300 W) for 30 min. The reaction mixture was then pouredonto brine (50 mL) and extracted with EtOAc (2×20 mL). The organicphases were combined then dried over MgSO₄, filtered, and subsequentlyevaporated under reduced pressure. The resulting residue was purified bysilica gel column chromatography eluting with hexane/EtOAc (90:10 to80:20) to furnish II as a colourless oil (37 mg, 64%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.40-8.32 (m, 2H), 7.58-7.47 (m, 1H),7.32-7.18 (m, 4H), 7.14 (d, J=8.5 Hz, 1H), 6.99 (s, 1H), 6.91-6.82 (m,2H), 4.23 (t, J=7.5 Hz, 2H), 4.12 (q, J=7.0 Hz, 2H), 2.30 (s, 3H), 2.27(t, J=7.5 Hz, 2H), 1.75 (quin, J=7.4 Hz, 2H), 1.61 (quin, J=7.0 Hz, 2H),1.46-1.32 (m, 4H), 1.25 (t, J=7.3 Hz, 3H). MW: 417.54. LCMS (ES). found418.2 [MH]⁺.

7-[Pyridin-2-yl-(4-o-tolyl-pyridin-2-yl)-amino]-heptanoic acidhydroxyamide (III)

HONH₂ (50% aqueous, 2 mL) was added to II (37 mg, 0.09 mmol) in DMF (0.5mL) and MeOH (2 mL) at rt. The reaction mixture was stirred for 22 h,after which the solvents were evaporated under reduced pressure. Theresulting residue was dissolved and co-evaporated with toluene (2×2 mL)then was purified by silica gel column chromatography eluting withCH₂Cl₂/MeOH (100:4 to 100:8) to furnish III as a yellow oil (20 mg,55%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.41-8.33 (m, 2H), 7.57 (t, J=7.8 Hz,1H), 7.32-7.22 (m, 3H), 7.19 (d, J=7.0 Hz, 1H), 7.12 (d, J=8.0 Hz, 1H),6.95 (s, 1H), 6.91 (dd, J=5.5, 7.0 Hz, 1H), 6.88 (d, J=4.5 Hz, 1H), 4.21(t, J=7.5 Hz, 2H), 2.29 (s, 3H), 2.22-2.13 (m, 2H), 1.80-1.60 (m, 4H),1.44-1.32 (m, 4H). MW: 404.50. LCMS (ES). found 405.2 [MH]⁺.

Example 257-{[4-(2-Chloro-phenyl)-pyridin-2-yl]-pyridin-2-yl-amino}-heptanoic acidhydroxyamide

7-{[4-(2-Chloro-phenyl)-pyridin-2-yl]-pyridin-2-yl-amino}-heptanoic acidethyl ester (II)

Compound I (55 mg, 0.116 mmol, prepared using the method outlined abovefor Example 21), Pd(PPh₃)₄ (14 mg, 0.012 mmol), 2-chlorophenylboronicacid (36 mg, 0.231 mmol) and potassium carbonate (64 mg, 0.46 mmol) werestirred in toluene (3 mL) and water (1.5 mL) at 120° C. under microwaveirradiation (300 W) for 30 min. The reaction mixture was then pouredonto brine (50 mL) and extracted with EtOAc (2×20 mL). The organicphases were combined then dried over MgSO₄, filtered, and subsequentlyevaporated under reduced pressure. The resulting residue was purified bysilica gel column chromatography eluting with hexane/EtOAc (90:10 to80:20) to furnish II as a colourless oil (19 mg, 38%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.43 (d, J=5.0 Hz, 1H), 8.38 (d, J=4.0Hz, 1H), 7.62-7.53 (m, 1H), 7.49-7.45 (m, 1H), 7.37-7.29 (m, 3H), 7.17(d, J=8.5 Hz, 1H), 7.12 (s, 1H), 7.00-6.95 (m, 1H), 6.92-6.84 (m, 1H),4.26 (t, J=7.3 Hz, 2H), 4.11 (q, J=7.0 Hz, 2H), 2.27 (t, J=7.5 Hz, 2H),1.76 (quin, J=7.0 Hz, 2H), 1.61 (quin, J=7.5 Hz, 2H), 1.45-1.33 (m, 4H),1.25 (t, J=7.0 Hz, 3H). MW: 437.96. LCMS (ES). found 438.2 [MH]⁺.

7-{[4-(2-Chloro-phenyl)-pyridin-2-yl]-pyridin-2-yl-amino}-heptanoic acidhydroxyamide (III)

HONH₂ (50% aqueous, 2 mL) was added to II (19 mg, 0.043 mmol) in DMF(0.5 mL) and MeOH (2 mL) at rt. The reaction mixture was stirred for 22h, after which the solvents were evaporated under reduced pressure. Theresulting residue was dissolved and co-evaporated with toluene (2×2 mL)then was purified by silica gel column chromatography eluting withCH₂Cl₂/MeOH (100:4 to 100:7) to furnish III as a pale blue oil (8 mg,44%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.42 (d, J=5.5 Hz, 1H), 8.38 (d, J=4.5Hz, 1H), 7.62-7.56 (m, 1H), 7.52-7.45 (m, 1H), 7.36-7.29 (m, 3H), 7.16(d, J=8.5 Hz, 1H), 7.10 (s, 1H), 6.98 (d, J=4.5 Hz, 1H), 6.92 (t, J=5.5Hz, 1H), 4.24 (t, J=7.5 Hz, 2H), 2.19 (t, J=6.8 Hz, 2H), 1.74 (quin,J=7.0 Hz, 2H), 1.65 (quin, J=7.0 Hz, 2H), 1.48-1.29 (m, 4H). MW: 424.92.LCMS (ES). found 425.1 [MH]⁺.

Example 267-{[4-(2-Fluoro-phenyl)-pyridin-2-yl]-pyridin-2-yl-amino}-heptanoic acidhydroxyamide

7-{[4-(2-Fluoro-phenyl)-pyridin-2-yl]-pyridin-2-yl-amino}-heptanoic acidethyl ester (II)

Compound I (56 mg, 0.117 mmol, prepared using the method outlined abovefor Example 21), Pd(PPh₃)₄ (13 mg, 0.012 mmol), 2-fluorophenylboronicacid (33 mg, 0.235 mmol) and potassium carbonate (65 mg, 0.47 mmol) werestirred in toluene (3 mL) and water (1.5 mL) at 120° C. under microwaveirradiation (300 W) for 40 min. The reaction mixture was then pouredonto brine (50 mL) and extracted with EtOAc (2×20 mL). The organicphases were combined then dried over MgSO₄, filtered, and subsequentlyevaporated under reduced pressure. The resulting residue was purified bysilica gel column chromatography eluting with hexane/EtOAc (90:10 to85:15) to furnish II as a colourless oil (20 mg, 41%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.42 (d, J=5.5 Hz, 1H), 8.37 (dd, J=1.0,5.0 Hz, 1H), 7.60-7.50 (m, 1H), 7.43 (dt, J=1.8, 7.7 Hz, 1H), 7.38 (tdd,J=2.6, 5.1, 10.4 Hz, 1H), 7.26-7.20 (m, 2H), 7.19-7.12 (m, 2H), 7.06 (d,J=5.0 Hz, 1H), 6.88 (dd, J=5.5, 6.5 Hz, 1H), 4.24 (t, J=7.5 Hz, 2H),4.11 (q, J=7.4 Hz, 2H), 2.27 (t, J=7.5 Hz, 2H), 1.75 (quin, J=7.5 Hz,2H), 1.62 (quin, J=7.5 Hz, 2H), 1.46-1.32 (m, 4H), 1.26 (t, J=7.5 Hz,3H). MW: 421.51. LCMS (ES). found 422.2 [MH]⁺.

7-{[4-(2-Fluoro-phenyl)-pyridin-2-yl]-pyridin-2-yl-amino}-heptanoic acidhydroxyamide (III)

HONH₂ (50% aqueous, 2 mL) was added to II (30 mg, 0.07 mmol) in DMF (0.5mL) and MeOH (2 mL) at rt. The reaction mixture was stirred for 22 h,after which the solvents were evaporated under reduced pressure. Theresulting residue was dissolved and co-evaporated with toluene (2×2 mL)then was purified by silica gel column chromatography eluting withCH₂Cl₂/MeOH (100:4 to 100:7) to furnish III as a white wax (15 mg, 79%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.41 (d, J=5.5 Hz, 1H), 8.37 (d, J=4.0Hz, 1H), 7.61-7.54 (m, 1H), 7.42 (dt, J=1.5, 7.5 Hz, 1H), 7.40-7.35 (m,1H), 7.25-7.19 (m, 2H), 7.19-7.10 (m, 2H), 7.08 (d, J=5.0 Hz, 1H), 6.90(dd, J=5.3, 6.8 Hz, 1H), 4.21 (t, J=7.0 Hz, 2H), 2.15 (t, J=6.8 Hz, 2H),1.72 (quin, J=7.5 Hz, 2H), 1.64 (quin, J=7.0 Hz, 2H), 1.44-1.31 (m, 4H).MW: 408.47. LCMS (ES). found 409.2 [MH]⁺.

Example 27 7-[Pyridin-2-yl-(4-m-tolyl-pyridin-2-yl)-amino]-heptanoicacid hydroxyamide

7-[Pyridin-2-yl-(4-m-tolyl-pyridin-2-yl)-amino]heptanoic acid ethylester (II)

Compound I (56 mg, 0.117 mmol, prepared using the method outlined abovefor Example 21), Pd(PPh₃)₄ (14 mg, 0.013 mmol), m-tolylboronic acid (32mg, 0.235 mmol) and potassium carbonate (65 mg, 0.47 mmol) were stirredin toluene (3 mL) and water (1.5 mL) at 120° C. under microwaveirradiation (300 W) for 30 min. The reaction mixture was then pouredonto brine (30 mL) and extracted with EtOAc (2×20 mL). The organicphases were combined then dried over MgSO₄, filtered, and subsequentlyevaporated under reduced pressure. The resulting residue was purified bysilica gel column chromatography eluting with hexane/EtOAc (90:10 to80:20) to furnish II as a colourless oil (41 mg, 84%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.39 (d, J=5.0 Hz, 1H), 8.37 (dd, J=1.3,5.3 Hz, 1H), 7.57-7.50 (m, 1H), 7.39-7.32 (m, 3H), 7.27 (br. s, 1H),7.23 (d, J=6.5 Hz, 1H), 7.13-7.07 (m, 2H), 6.87 (dd, J=5.3, 6.8 Hz, 1H),4.23 (t, J=7.0 Hz, 2H), 4.11 (q, J=7.5 Hz, 2H), 2.42 (s, 3H), 2.27 (t,J=7.5 Hz, 2H), 1.75 (quin, J=7.4 Hz, 2H), 1.62 (quin, J=7.5 Hz, 2H),1.45-1.31 (m, 4H), 1.25 (t, J=7.3 Hz, 3H). MW: 417.54. LCMS (ES). found418.2 [MH]⁺.

7-[Pyridin-2-yl-(4-m-tolyl-pyridin-2-yl)-amino]heptanoic acidhydroxyamide (III)

HONH₂ (50% aqueous, 2 mL) was added to II (31 mg, 0.074 mmol) in DMF(0.5 mL) and MeOH (2 mL) at rt. The reaction mixture was stirred for 24h, after which the solvents were evaporated under reduced pressure. Theresulting residue was dissolved and co-evaporated with toluene (2×2 mL)then was purified by silica gel column chromatography eluting withCH₂Cl₂/MeOH (100:4 to 100:7) to furnish III as a colourless oil (18 mg,62%).

¹H NMR (400 MHz, CDCl₃) δ_(H): 8.43-8.34 (m, 2H), 7.57 (t, J=7.0 Hz,1H), 7.38-7.32 (m, 3H), 7.24 (br. s, 2H), 7.14 (d, J=4.5 Hz, 1H), 7.09(d, J=8.0 Hz, 1H), 6.91 (dd, J=5.3, 6.8 Hz, 1H), 4.22 (t, J=7.3 Hz, 2H),2.42 (s, 3H), 2.19-2.10 (m, 2H), 1.77-1.63 (m, 4H), 1.48-1.32 (m, 4H).MW: 404.50. LCMS (ES). found 405.2 [MH]⁺.

We claim:
 1. A compound of the formula

wherein: . . . is a double bond and X is C; or . . . is a single bondand X is N, CH or CQR₁; and wherein: n is 1 to 10; R is H or QR₁; eachR′ is independently selected from H and QR₁; each Q is independentlyselected from a bond, CO, NH, S, SO, SO₂ and O; each R₁ is independentlyselected from C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, aryl,heteroaryl, acyl, C₁-C₁₀ cycloalkyl, halogen, C₁-C₁₀ alkylaryl andC₁-C₁₀ heterocycloalkyl; L is a nitrogen-containing heteroaryl; W is azinc-chelating residue; and wherein each of the R₁ and L groups can beoptionally substituted, or a pharmaceutically acceptable salt thereof.2. The compound according to claim 1, wherein at least one L is pyridylor a benzofused pyridyl.
 3. The compound according to claim 1, wherein Wis selected from:


4. The compound according to claim 3, wherein W is —COOH, —CONHOH,—CONHSO₂CH₃, —CONHNHSO₂CH₃, —CONHNH₂, —CONH(2-pyridyl) or —NHCONHOH. 5.The compound according to claim 4, wherein W is —CONHOH.
 6. The compoundaccording to claim 1, wherein at least one R′ is H, C₁-C₁₀ alkyl orO—(C₁-C₁₀ alkyl).
 7. The compound according to claim 1, wherein at leastone R′ is substituted or unsubstituted aryl or O-(substituted orunsubstituted aryl).
 8. The compound according to claim 7, wherein atleast one R′ is aryl substituted with a halogen, amino or C₁-C₁₀ alkyl;or is O-aryl substituted with a halogen, amino or C₁-C₁₀ alkyl.
 9. Thecompound according to claim 1, wherein n is 3 to
 6. 10. The compoundaccording to claim 1, wherein X

is C═.
 11. The compound according to claim 1, wherein X

is N—.
 12. The compound according to claim 1, as exemplified herein. 13.A pharmaceutical composition comprising a compound according to claim 1,and a pharmaceutically acceptable carrier or diluent.
 14. Thecomposition according to claim 13, which is in a form suitable for oral,rectal, parenteral, intranasal or transdermal administration oradministration by inhalation or by suppository.
 15. A product containing(a) a compound according to claim 1, and (b) another inhibitor of histone deacetylase (HDAC).
 16. A product containing (a) a compoundaccording to claim 1, and (b) another chemotherapeutic or antineoplasticagent.
 17. A method for treating or preventing a condition mediated byhistone deacetylase (HDAC), wherein said method comprises administering,to a patient in need of such treatment or prevention, a compound ofclaim
 1. 18. The method according to claim 17, wherein the condition iscancer, cardiac hypertrophy, chronic heart failure, an inflammatorycondition, a cardiovascular disease, a haemoglobinopathy, a thalassemia,a sickle cell disease, a CNS disorder, an autoimmune disease, diabetes,osteoporosis, MDS, benign prostatic hyperplasia, endometriosis, oralleukoplakia, a genetically related metabolic disorder, an infection,Rubens-Taybi, fragile X syndrome, alpha-1 antitrypsin deficiency,chronic lymphocytic leukaemia, breast cancer, prostate cancer, ovariancancer, mesothelioma, T-cell lymphoma, cardiac hypertrophy, chronicheart failure, a skin inflammatory condition, a musculoskeletalinflammatory condition, or an inflammatory condition of thegastrointestinal tract.
 19. The method according to claim 17, for use inaccelerating wound healing, protecting hair follicles, or as animmunosuppressant.